Pergamon

Thrombosis Research 88 (1997) 509–520

THROMBOSIS RESEARCH

Author Index—Volumes 81–84 (1996)

Aasen, A.O., see Karlsrud, T.S. **82:**265
Abbate, R., see Boddi, M. **82:**207
———, see Chiarantini, E. **82:**137
———, see Comeglio, P. **84:**199
———, see Gensini, G.F. **84:**1
———, see Martini, F. **83:**299
Abe, S., see Goto, S. **84:**351
Abella, A., see Keddad, K. **82:**159
Abildgaard, U., see Andersson, T. **82:**109
———, see Iversen, N. **84:**267
Abruzzese, G., see Avellone, G. **81:**277
Aguejouf, O., see Belougne, E. **82:**453, **84:**189, 207
———, see Imbault, P. **82:**469
Ahlburg, P., see Knudsen, L. **84:**45
Ajenjo, C., see Aranda, E. **84:**67
Akay, H., see Özdemir, O. **84:**121
Akın, R., see Tanındı, Ş. **81:**471
Albanese, A., see Magnani, A. **81:**383
Alessandri, C., see Basili, S. **84:**279
Aljada, A., see Dandona, P. **81:**163
Amirkhosravi, A., J.P. Biggerstaff, G. Warnes, D.A. Francis, J.L. Francis. Determination of tumor cell procoagulant activity by Sonoclot™ analysis in whole blood. **84:**323
Andersen, B.S., see Rahr, H.B. **81:**607
Anderson, S.M., see Maciejewski, J.P. **83:**433
Andersson, T., B. Lorentzen, H. Høgdahl, T. Clausen, M.-C. Mowinckel, U. Abildgaard. Thrombin-inhibitor complexes in the blood during and after delivery. **82:**109
André, P., P. Hainaud, C. Bal dit Sollier, V. Drouet, L.I. Garfinkel, A. Uzan, J.P. Caen, L.O. Drouet. Guinea pig blood: a model for the pharmacologic modulation of the GPIb/IX-VWF axis. **83:**127
André, P., see Roussi, J. **81:**297
Anfossi, G., P. Massucco, L. Mattiello, V. Piretto, E. Mularoni, F. Cavalot, G. Paoletti, M. Trovati. Insulin exerts opposite effects on platelet function at physiological and supraphysiological concentrations. **82:**57
Ankri, A., see Bastard, J.-P. **81:**271
Aoki, N., see Ikematsu, S. **82:**129
Aoki, T., D. Cox, K. Senzaki, J. Seki, A. Tanaka, H. Takasugi, Y. Motoyama. The anti-platelet and anti-thrombotic effects of FK633, a peptide-mimetic GPIIb/IIIa antagonist. **81:**439
Aranda, E., J. Pereira, C. Ajenjo, C. Prieto, S. Sepúlveda, D. Mezzano. Human intraplatelet 5-hydroxytryptamine is correlated with mean platelet survival time. **84:**67
Arcieri, P., see Coniglio, M. **83:**183
Ardlie, N.G., see Selley, M.L. **83:**449
Ariyoshi, H., see Kambayashi, J.-i. **81:**85
Asazuma, N., see Qi, R. **81:**43
———, see Satoh, K. **81:**515
Aschka, I., see Nowak-Göttl, U. **81:**665
Ataullakhanov, F.I., see Zarnitsina, V.I. **84:**225, 333
Atkinson, A., see Bessos, H. **84:**367
———, see Huggan, P.J. **81:**339
Austin, H., see Hooper, W.C. **81:**577
Avellone, G., V. Di Garbo, R. Cordova, G. Abruzzese, G. Rotolo, R. De Simone, G. Raneli, G. Bompiani. Activation of coagulation but normal fibrinolysis in patients with type II_a hyperlipoproteinemia. **81:**277
Aznar, J., see Jorquera, J.I. **82:**217
———, see Martínez, M. **83:**375
Azougagh Oualane, F., see Belougne, E. **82:**453
———, see Doutremepuich, C. **83:**217
Azzadin, A., see Mysliwiec, J. **83:**175

Baba, S., see Rydzewski, A. **84:**445
Bach-Gansmo, E.T., S. Halvorsen, H.C. Godal, O.H. Skjønsberg. D-dimers are degraded by human neutrophil elastase. **82:**177
Badimon, J.J., see Pueyo, C. **81:**101
Badimon, L., see Pueyo, C. **81:**101
Baglin, T.P., see Rota, S. **83:**329
Baillie, J., see Bessos, H. **84:**367
Baj, Z., see Golański, J. **83:**199
Bal dit Sollier, C., L. Drouet, G. Pignaud, C. Chevallier, J. Caen, A.-M. Fiat, C. Izquierdo, P. Jollès. Effect of κ-casein split peptides on platelet aggregation and on thrombus formation in the guinea-pig. **81:**427
Bal dit Sollier, C., see André, P. **83:**127
Balestrieri, A., see Marongiu, F. **84:**379
Balle Petersen, L., see Stephens, R.W. **84:**453
Bangalore, N., see Lee, T.K. **82:**225
Bara, L., see Gerotziafas, G.T. **81:**491
———, see Tardy, B. **83:**153
Barbanti, M., see Dettori, A.G. **83:**103
Barbucci, R., see Magnani, A. **81:**383
Barcellona, D., G. Mameli, F. Marongiu. Inhibition of blood coagulation activation and oral anticoagulants in patients with mechanical heart valve prostheses. **81:**403
Barcellona, D., see Marongiu, F. **84:**379
Barış, İ., see Özdemir, O. **84:**121
Barışta, İ., see Demiroğlu, H. **84:**297
Bark, N., B. Blombäck, K. Fatah. On the occurrence of thrombin-like enzymes in mosquitoes. **81:**623
Barna, L., see Hoagland, L.E. **83:**363
———, see Peng, F. **82:**193, **83:**243
Basili, S., P. Ferroni, F.M. Pulcinelli, G. Pettirossi, M. Vieri, F. Violi, C. Alessandri, C. Cordova, P.P. Gazzaniga. Potential usefulness of antiplatelet agents in patients with chronic obstructive pulmonary disease. **84:**279
Bastard, J.-P., E. Bruckert, D. Porquet, C. Jardel, A. Ankri, J. Delattre, B. Hainque. Evidence for a relationship between plas-

0049-3848/97 $17.00 + .00 © 1998 Elsevier Science Ltd. Printed in the USA. All rights reserved.
PII S0049-3848(98)00057-7

minogen activator inhibitor-1 and gamma glutamyl transferase. **81:**271
Baussan, Ch., see Keddad, K. **82:**159
Bayram, Ç., see Süer, S. **83:**77
Bean, C., see Lacroix, K.A. **81:**133
Becher, H., see Grau, A.J. **82:**245
Beck, E.A., see Steinmann, C. **81:**145
Beckmann, R., see Zehetgruber, M. **83:**143
Bednar, J., see Sinzinger, H. **82:**291
Bellaiche, L., see Knudsen, L. **84:**45
Belougne, E., O. Aguejouf, F. Doutremepuich, C. Doutremepuich. Action of neurotransmitters: acetylcholine, adrenaline and serotonin on arterial thrombosis induced by a laser beam. **84:**189
———. Aspirin fails to prevent experimental arterial thrombosis induced by oxygen free radicals. **84:**207
Belougne, E., O. Aguejouf, P. Imbault, F. Azougagh Oualane, F. Doutremepuich, M.T. Droy-Lefaix, C. Doutremepuich. Experimental thrombosis model induced by laser beam. Application of aspirin and an extract of Ginkgo Biloba: EGb 761. **82:**453
Belougne, E., see Inamo, J. **83:**229
Bennick, A., U. Haddeland, F. Brosstad. D-dimer specific monoclonal antibodies react with fibrinogen aggregates. **82:**169
Benson, J., see Hooper, W.C. **81:**577
Benson, J.M., D.J. Phillips, B.P. Holloway, B.L. Evatt, W.C. Hooper. Oligonucleotide ligation assay for detection of the factor V mutation (Arg^{506}→Gln) causing protein C resistance. **83:**87
Bergonzini, G.L., see Mascellani, G. **84:**21
Bergqvist, D., see Henriksson, A.E. **82:**409
Bertrand, J.C., see Tardy, B. **83:**153
Bessos, H., A. Atkinson, A. McGill, J. Baillie, J. Seghatchian, M. Vickers, D. Bishop, N. Tandy, W.G. Murphy. Apheresis platelet concentrates: correlation of day one levels of *in vitro* quality markers with corresponding levels on days two to five of storage. **84:**367
Bessos, H., see Huggan, P.J. **81:**339
Bevers, E.M., see Smeets, E.F. **81:**419
Bianchini, P., see Mascellani, G. **84:**21
Bichler, J., J.A. Heit, W.G. Owen. Detection of thrombin in human blood by ex-vivo hirudin. **84:**289
Biggerstaff, J.P., see Amirkhosravi, A. **84:**323
Billett, H.H., see Kheiri, S.A. **82:**43
Binder, B.R., see Grubic, N. **84:**431
———, see Zehetgruber, M. **83:**143
Biondi, G., see Marongiu, F. **84:**379
Bishop, D., see Bessos, H. **84:**367
Bloch, M.F., see Gerotziafas, G.T. **81:**491
Blombäck, B. Fibrinogen and fibrin—proteins with complex roles in hemostasis and thrombosis. **83:**1
——— Walter H. Seegers—An appreciation (Obituary). **84:**305
———, see Bark, N. **81:**623
Boddi, M., D. Prisco, S. Fedi, A.P. Cellai, A.A. Liotta, E. Parretti, F. Mecacci, G. Mello, R. Abbate. Antiphospholipid antibodies and pregnancy disorders in women with insulin dependent diabetes. **82:**207. Correction. **84:**299
Boddi, V., see Martini, F. **83:**299
Boeri, G., see Cella, G. **81:**671
Bohgaki, M., see Wanaka, K. **82:**79
Bompiani, G., see Avellone, G. **81:**277
Bonnar, J., see Norris, L.A. **81:**407
Bonneau, M., see Roussi, J. **81:**297
Borris, L.C., see Rahr, H.B. **81:**607
Bostwick, J.S., C.J. Kasiewski, V. Chu, S.I. Klein, R.D. Sabatino, M.H. Perrone, C.T. Dunwiddie, J.J. Cook, R.J. Leadley, Jr. Anti-thrombotic activity of RG13965, a novel platelet fibrinogen receptor antagonist. **82:**495
Bottasso, B., D. Mari, R. Coppola, N. Santoro, M. Vaglini, P.M. Mannucci. Hypercoagulability and hyperfibrinolysis in patients with melanoma. **81:**345
Boutcher, P.A., P.J. Gaffney, S. Raut, R.G. O'Regan, P. McLoughlin. Effects of early plasmin digests of fibrinogen on isometric tension development in isolated rings of rat pulmonary artery. **81:**231
Box, L., see Lacroix, K.A. **81:**133
Brandt, J.T., see McAndrew, P.E. **83:**195
Bregengaard, C., see Holst, J. **81:**461
Brodniewicz, T., see Cierniewski, C.S. **82:**349
Brosstad, F., see Bennick, A. **82:**169
Brown, N.L., see Millet, J. **81:**497
Bruckert, E., see Bastard, J.-P. **81:**271
Buczko, W., see Chabielska, E. **82:**69
———, see Malyszko, J. **83:**351
———, see Mysliwiec, J. **83:**175
———, see Pawlak, D. **83:**189
Buggle, F., see Grau, A.J. **82:**245
Buø, L., see Karlsrud, T.S. **82:**265
Burke, S.E., D.J. Davidson, N.L. Lubbers, I.M. Reininger, J. Henkin. Differential effects of lys- and mini- plasminogen on clot lysis induced by recombinant urokinase and recombinant prourokinase in a canine thrombosis model. **83:**421
Bussel, J.A., see Pfaffenbach, G.M. **81:**353
Byrne, C.D., see Rota, S. **83:**329

Caen, J., see Bal dit Sollier, C. **81:**427
Caen, J.P., see André, P. **83:**127
Callas, D., see Hayes, J.M. **82:**187
———, see Yang, L.H. **81:**555
Callas, D.D., J. Fareed. Comparative studies on the antithrombin potency of various thrombin inhibitors, as determined by using an amidolytic method. **83:**97
———. Comparative anticoagulant effects of various thrombin inhibitors, as determined in the ecarin clotting time method. **83:**463
Camerer, E., A.-B. Kolstø, H. Prydz. Cell biology of tissue factor, the principal initiator of blood coagulation. **81:**1
Canova, N., see Dettori, A.G. **83:**103
Cardigan, R.A., I.J. Mackie, S.J. Machin. The effect of heparin and its neutralisation on functional assays for factor VIIa, factor VII and TFPI. **84:**237
Carmena, R., see Martínez, M. **83:**375
Casaña, P., see Jorquera, J.I. **82:**217
Casey, M.C., P.T. Murphy, V. Mitchell, J. Lunec. Specific markers of bone formation in total protein S deficient patients (Letter to the Editors-in-Chief). **84:**223. Correction. **84:**482
Cavalli, E., see Cignarella, A. **84:**311
Cavalot, F., see Anfossi, G. **82:**57
Cazenave, J.-P., see Kretz, J.-G. **84:**391
Cella, G., U. Vertolli, A. Naso, A. Vianello, E. Rampin, A. Sbarai, G. Boeri, W.E. Strauss. Tissue factor pathway inhibitor (TFPI) activity in uremic patients during hemodialysis. **81:**671
Cellai, A.P., see Boddi, M. **82:**207
———, see Chiarantini, E. **82:**137
———, see Comeglio, P. **84:**199
———, see Martini, F. **83:**299
Chabielska, E., V. Kolpakov, M.C. D'Adamo, A. De Curtis, W. Buczko, L. Iacoviello, M.B. Donati. Morphological and hemostatic changes in rats with abdominal arterial prosthesis. **82:**69
Chabielska, E., see Mysliwiec, J. **83:**175
Chakfe, N., see Kretz, J.-G. **84:**391
Chalas, J., see Keddad, K. **82:**159

Chang, B.-I., see Shi, G.-Y. **81:**75
Chang, W.-C., see Shi, G.-Y. **81:**75
Cheung, W.-F., D.W. Stafford, T. Sugo. Localization of a calcium-dependent epitope to the amino terminal region of the Gla domain of human factor IX. **81:**65
Chevallier, C., see Bal dit Sollier, C. **81:**427
Chiang, T.M. Effect of monoclonal antibody on the adhesion of platelets to aortic segments. **84:**345
Chiang, T.M., E.S. Kang, A.H. Kang. Involvement of phosphoprotein phosphatase 1 in collagen-platelet interaction. **84:**399
Chiarantini, E., R. Valanzano, A.A. Liotta, A.P. Cellai, S. Fedi, I. Ilari, D. Prisco, F. Tonelli, R. Abbate. Hemostatic abnormalities in inflammatory bowel disease. **82:**137
Chiarantini, E., see Comeglio, P. **84:**199
———, see Martini, F. **83:**299
Chiu, L., see Faung, S.-T. **81:**91
Chong, B.H., see Vun, C.M. **81:**525
Chou, T.-C., L.-Y. Hsu, M.-H. Yen, Y.-A. Ding. The inhibitory effect of 2-thienyl 2′-hydroxyphenyl ketone (C85) on platelet thromboxane formation. **84:**83
Christ, G., see Zehetgruber, M. **83:**143
Chu, V., see Bostwick, J.S. **82:**495
Cicala, C., see Itoh, H. **83:**405
Cierniewski, C.S., E. Pluskota, M. Cieslak, T. Brodniewicz, M. Nowotarski. Antigenic properties of fibrinogen component of Hemaseel™ HMN subjected to the antiviral severe dry heat treatment. **82:**349
Cieslak, M., see Cierniewski, C.S. **82:**349
Cignarella, A., M. Nastasi, E. Cavalli, L. Puglisi. Novel lipid-lowering properties of *Vaccinium myrtillus* L. leaves, a traditional antidiabetic treatment, in several models of rat dyslipidaemia: a comparison with ciprofibrate. **84:**311
Cines, D., see Higazi, A.A.-R. **84:**243
Clausen, T., see Andersson, T. **82:**109
Cloherty, T., E.A. Golden, S.E. Lind. Use of a modified activated partial thromboplastin time to detect lupus anticoagulants. **83:**137
Col-De Beys, C., see Schlit, A.-F. **84:**203
Comeglio, P., S. Fedi, A.A. Liotta, A.P. Cellai, E. Chiarantini, D. Prisco, F. Mecacci, E. Parretti, G. Mello, R. Abbate. Blood clotting activation during normal pregnancy. **84:**199
Comfurius, P., see Smeets, E.F. **81:**419
Coniglio, M., A. Platania, G.D. Di Nucci, P. Arcieri, R. Modzrewska, G. Mariani. Antiphospholipid-protein antibodies are not an uncommon feature in retinal venous occlusions. **83:**183
Cook, J.J., see Bostwick, J.S. **82:**495
Coppola, R., see Bottasso, B. **81:**345
Cordova, C., see Basili, S. **84:**279
Cordova, R., see Avellone, G. **81:**277
Cox, D., see Aoki, T. **81:**439
Crain, E.J., Jr., see Wong, P.C. **83:**117
Cunningham, D., see Finch, C.N. **81:**679
Curats, R., see Jorquera, J.I. **82:**217

Dachary-Prigent, J., see Pasquet, J.-M. **82:**509
D'Adamo, M.C., see Chabielska, E. **82:**69
Dahlbäck, B., see Zöller, B. **83:**475
Dandona, P., K. Thusu, U. Khurana, J. Love, A. Aljada, S. Mousa. Calcium, calmodulin and protein kinase C dependence of platelet shape change. **81:**163
Daniel, J.L., see Strouse, R.J. **82:**485
Danielsen, D., see Rahr, H.B. **81:**607
Davidson, D.J., see Burke, S.E. **83:**421
Davidson, S., see Denson, K.W.E. **81:**151
Davies, J.A., see Hughes, J.R. **84:**217
Davies, M.J. The contribution of thrombosis to the clinical expression of coronary atherosclerosis. **82:**1
de Castellarnau, C., see Pich, I. **82:**323
De Curtis, A., see Chabielska, E. **82:**69
Dehmer, G.J., see Melton, L.G. **83:**265
De La Cruz, J.P., A. Moreno, F. Mérida, J. García Campos, F. Sánchez de la Cuesta. The pyrimido-pyrimidine derivatives, dipyridamole, mopidamol and RA-642, prevent from retinal vascular defects in experimental diabetes mellitus. **81:**327
De La Cruz, J.P., see González-Correa, J.A. **81:**367
Delattre, J., see Bastard, J.-P. **81:**271
de Maat, M., see Myrup, B. **81:**485
Demiroğlu, H., İ. Barışta, S. Dündar. Assessing the risk of deep vein thrombosis in Behçet's disease (Letter to the Editors-in-Chief). **84:**297
Dempfle, C.-E., see Vogel, G. **81:**241
Denson, K.W.E., M.E. Haddon, S.V. Reed, S. Davidson, T.J. Littlewood. A more discriminating test for APC resistance and a possible screening test to include protein C and protein S. **81:**151
de Romeuf, C., C. Mazurier. Interest of a simple and fast method for platelet von Willebrand factor characterization. **83:**287
De Simone, R., see Avellone, G. **81:**277
Dettori, A.G., V. Zamboni, C. Manotti, N. Canova, M. Barbanti, E. Palazzini. Pharmacology of a new low molecular weight dermatan sulphate (Desmin) in healthy volunteers: repeated daily intramuscular administration of 400 mg for a week. **83:**103
Devitt, M., see Norris, L.A. **81:**407
Dhall, D.P., see van Gelder, J.M. **82:**33
Di Garbo, V., see Avellone, G. **81:**277
Dilley, A., see Hooper, W.C. **81:**577
Ding, Y.-A., see Chou, T.-C. **84:**83
Di Nucci, G.D., see Coniglio, M. **83:**183
Djurhuus, C., see Knudsen, L. **84:**45
Dolara, A., see Martini, F. **83:**299
Donati, M.B., see Chabielska, E. **82:**69
Dorner, F., see Fischer, B.E. **81:**157, **84:**55
Douglas, G.J., see Itoh, H. **83:**405
Doutremepuich, C., F. Azougagh Oualane, F. Doutremepuich, J. Fareed. New class of heparin derivatives with a potent antithrombotic effect and a very limited hemorrhagic activity. **83:**217
Doutremepuich, C., see Belougne, E. **82:**453, **84:**189, 207
———, see Imbault, P. **82:**469
———, see Inamo, J. **83:**229
Doutremepuich, F., see Belougne, E. **82:**453, **84:**189, 207
Doutremepuich, F., see Doutremepuich, C. **83:**217
Doutremepuich, F., see Imbault, P. **82:**469
Drasin, T., M. Sahud. Blood-type and age affect human plasma levels of histidine-rich glycoprotein in a large population. **84:**179
Drohan, W.N., see Lee, T.K. **82:**225
Drouet, L., see Bal dit Sollier, C. **81:**427
———, see Roussi, J. **81:**297
Drouet, L.O., see André, P. **83:**127
Drouet, V., see André, P. **83:**127
Droy-Lefaix, M.T., see Belougne, E. **82:**453
Dündar, S., see Demiroğlu, H. **84:**297
———, see Özdemir, O. **84:**121
Dunwiddie, C.T., see Bostwick, J.S. **82:**495

Edlinger, G., S. Gallistl, W. Muntean. Lupus anticoagulant and factor XII activity in children with prolonged PTT. **83:**403
Edwards, C.M., J.A. May, S. Heptinstall, K.C. Lowe. Effects of *Pluronic® F-68 (Poloxamer-188) on platelet aggregation in human whole blood (Letter to the Editors-in-Chief).* **81:**511
Efthimiou, Y., see Pirich, C. **81:**213
Eibl, J., see Fischer, B.E. **84:**55

Elikowski, W., see Lewandowski, K. **81:**615
Elsayed, Y.A., see Kato, K. **82:**335
Emri, S., see Özdemir, O. **84:**121
Ernofsson, M., A. Siegbahn. Platelet-derived growth factor-BB and monocyte chemotactic protein-1 induce human peripheral blood monocytes to express tissue factor. **83:**307
Evans, S., see Vun, C.M. **81:**525
Evatt, B.L., see Benson, J.M. **83:**87
———, see Hooper, W.C. **81:**315, 577
———, see Phillips, D.J. **81:**307
Ezban, M., see Holst, J. **81:**461

Fareed, J., see Callas, D.D. **83:**97, 463
———, see Doutremepuich, C. **83:**217
———, see Hayes, J.M. **82:**187
———, see Kaiser, B. **82:**257
———, see Yang, L.H. **81:**555, **84:**167
Fasy, T.M., see Kheiri, S.A. **82:**43
Fatah, K., see Bark, N. **81:**623
Faung, S.-T., L. Chiu, C.-T. Wang. Platelet lysis and functional perturbation by 13-methyl myristate. The major fatty acid in *Flavobacterium ranacida*. **81:**91
Fedi, S., see Boddi, M. **82:**207
———, see Chiarantini, E. **82:**137
———, see Comeglio, P. **84:**199
———, see Martini, F. **83:**299
Feigen, L.P., see Pueyo, C. **81:**101
Fernández, M.A., see Jorquera, J.I. **82:**217
Ferro, L., see Fisher, J. **81:**55
Ferroni, P., see Basili, S. **84:**279
Fiat, A.-M., see Bal dit Sollier, C. **81:**427
Finch, C.N., V.A. Lyle, D. Cunningham, J.L. Miller. Expression of human platelet glycoprotein Ibβ in insect cells. **81:**679
Fischer, B.E., G. Kramer, A. Mitterer, L. Grillberger, M. Reiter, W. Mundt, F. Dorner, J. Eibl. Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII. **84:**55
Fischer, B.E., A. Mitterer, F. Dorner. Qualitative and quantitative detection of human and recombinant thrombin by binding to leech and recombinant hirudin immobilized at the solid phase. **81:**157
Fisher, J., T.K. Holland, R. Pescador, R. Porta, L. Ferro. Study on pharmacokinetics of radioactive labelled defibrotide after oral or intravenous administration in rats. **81:**55
Fliedner, M., see Vielhaber, H. **81:**651
Flynn, P.D., see Rota, S. **83:**329
Francis, D.A., see Amirkhosravi, A. **84:**323
Francis, J.L., see Amirkhosravi, A. **84:**323
Fujii, N., T. Kaji, C. Yamamoto, Y. Fujiwara, F. Koizumi. Phorbol 12-myristate 13-acetate stimulates the release of glycosaminoglycans from cultured vascular endothelial cells: possible involvement of protein kinase C activation. **82:**379
Fujitani, K., see Ikeda, M. **82:**87
Fujiwara, Y., see Fujii, N. **82:**379
———, see Kaji, T. **82:**389
Fukutake, K., see Ikematsu, S. **82:**129
Funatsu, A., see Kamikubo, Y.-i. **83:**161
Furlan, M., see Steinmann, C. **81:**145

Gabriel, D.A., see Melton, L.G. **83:**265
Gabriel, H., see Zehetgruber, M. **83:**143
Gaffney, P.J., see Boutcher, P.A. **81:**231
———, see Raut, S. **81:**503
Galanakis, D., G. Nuovo, S. Spitzer, C. Kaplan, I. Scharrer. Fibrinogen mRNA and antigen co-present in human trophoblasts in situ: possible implications. **81:**263
Gallistl, S., see Edlinger, G. **83:**403
García Campos, J., see De La Cruz, J.P. **81:**327
Garfinkel, L., see Gralnick, H.R. **81:**113
Garfinkel, L.I., see André, P. **83:**127
Gawaz, M., A. Reininger, F.-J. Neumann. Platelet function and platelet-leukocyte adhesion in symptomatic coronary heart disease. Effects of intravenous magnesium. **83:**341
Gazzaniga, P.P., see Basili, S. **84:**279
Gensini, G.F., S. Micheli, D. Prisco, R. Abbate. Menopause and risk of cardiovascular disease. **84:**1
Gensini, G.F., see Martini, F. **83:**299
Gerotziafas, G.T., L. Bara, M.F. Bloch, P.E. Makris, M.M. Samama. Treatment with LMWHs inhibits factor VIIa generation during *in vitro* coagulation of whole blood. **81:**491
Giddings, J.C., see Sawamoto, Y. **83:**279
Gil, L., see Martínez, M. **83:**375
Godal, H.C., see Bach-Gansmo, E.T. **82:**177
Gökçay, E., see Tanındı, Ş. **81:**471
Golański, J., T. Pietrucha, Z. Baj, J. Greger, C. Watala. Molecular insights into the anticoagulant-induced spontaneous activation of platelets in whole blood—various anticoagulants are not equal. **83:**199
Golden, E.A., see Cloherty, T. **83:**137
González-Correa, J.A., J.P. De La Cruz, M.I. Lucena, F. Sánchez de la Cuesta. Effect of cyclosporin A on platelet aggregation and thromboxane/prostacyclin balance in a model of extrahepatic cholestasis in the rat. **81:**367
Gori, A.M., see Martini, F. **83:**299
Goto, S., S. Handa, E. Takahashi, S. Abe, M. Handa, Y. Ikeda. Synergistic effect of epinephrine and shearing on platelet activation. **84:**351
Goto, Y., see Sakata, T. **81:**687
Gouault-Heilmann, M., C. Leroy-Matheron. Factor V Leiden-dependent APC resistance: improved sensitivity and specificity of the APC resistance test by plasma dilution in factor V-depleted plasma (Letter to the Editors-in-Chief). **82:**281
Graf, J., see Reininger, C.B. **81:**641, **82:**523
Gralnick, H.R., W.S. Kramer, L.P. McKeown, L. Garfinkel A. Pinot, S.B. Williams, H. Krutzsch. Platelet adhesion at high shear rates: the roles of von Willebrand factor/GPIb and the β_1 integrin $\alpha_5\beta_1$. **81:**113
Gram, J., see Myrup, B. **81:**485
Grau, A.J., F. Buggle, H. Becher, E. Werle, W. Hacke. The association of leukocyte count, fibrinogen and C-reactive protein with vascular risk factors and ischemic vascular diseases. **82:**245
Greger, J., see Golański, J. **83:**199
Greinacher, A., see Reininger, C.B. **81:**641
Grillberger, L., see Fischer, B.E. **84:**55
Groscolas, R., see Pöschl, J.M.B. **81:**283
Grubic, N., M. Stegnar, P. Peternel, A. Kaider, B.R. Binder. A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis. **84:**431
Grunebaum, L., see Kretz, J.-G. **84:**391
Gu, J., see Xia, L. **81:**477
Guo, Y., see Kessler, C. **84:**145
Guyotat, D., see Tardy, B. **83:**153

Hachiya, T., see Rydzewski, A. **84:**445
Hacke, W., see Grau, A.J. **82:**245
Haddeland, U., see Bennick, A. **82:**169
Haddon, M.E., see Denson, K.W.E. **81:**151
Hainaud, P., see André, P. **83:**127
Hainque, B., see Bastard, J.-P. **81:**271

Halvorsen, S., see Bach-Gansmo, E.T. **82:**177
Hamers, M.J.A.G., see Stephens, R.W. **84:**453
Hamuro, T., see Kamikubo, Y.-i. **83:**161
Hamwi, A., see Veitl, M. **82:**399
Handa, M., see Goto, S. **84:**351
Handa, S., see Goto, S. **84:**351
Hasenkam, J.M., see Knudsen, L. **84:**45
Hayashi, K., see Sawamoto, Y. **83:**279
Hayes, J.M., W. Jeske, D. Callas, O. Iqbal, J. Fareed. Comparative intravenous antithrombotic actions of heparin and site directed thrombin inhibitors in a jugular vein clamping model. **82:**187
Hedner, U., see Holst, J. **81:**461
Heikkilä, J., see Peltonen, S. **82:**459
Heit, J.A., see Bichler, J. **84:**289
Henkin, J., see Burke, S.E. **83:**421
Henriksson, A.E., T.K. Nilsson, U. Jansson, D. Bergqvist. Experimental haemorrhage and blood component transfusion in humans: no change in plasma concentration of thrombin-antithrombin complex and plasmin-antiplasmin complex. **82:**409
Heptinstall, S., see Edwards, C.M. **81:**511
Heran, C.L., see Schumacher, W.A. **81:**187
Herbert, J.M., see Yang, L.H. **81:**555
Higazi, A.A.-R., D. Cines. Regulation of single chain urokinase by small peptides. **84:**243
Hijikata-Okunomiya, A., see Wanaka, K. **82:**79
Hoagland, L.E., D.A. Triplett, F. Peng, L. Barna. APC-resistance as measured by a Textarin time assay: comparison to the APTT-based method. **83:**363
Hoffman, M., see Sumner, W.T. **81:**533
Høgdahl, H., see Andersson, T. **82:**109
Holland, T.K., see Fisher, J. **81:**55
Holloway, B.P., see Benson, J.M. **83:**87
Holme, S., see Owens, M.R. **81:**177
Holst, J., B. Lindblad, G. Westerlund, C. Bregengaard, M. Ezban, P.B. Østergaard, O. Nordfang, U. Hedner. Pharmacokinetics and delayed experimental anti-thrombotic effect of two domain non-glycosylated tissue factor pathway inhibitor. **81:**461
Hooper, W.C., A. Dilley, M.J.A. Ribeiro, J. Benson, H. Austin, V. Silva, P. Rawlins, N.K. Wenger, B.L. Evatt. A racial difference in the prevalence of the Arg506→Gln mutation. **81:**577
Hooper, W.C., D.J. Phillips, B.L. Evatt. TNF-α suppresses IL-6 upregulation of protein S in HepG-2 hepatoma cells. **81:**315
Hooper, W.C., see Benson, J.M. **83:**87
———, see Phillips, D.J. **81:**307
Hoppensteadt, D.A., see Yang, L.H. **84:**167
Horie, N., see Wanaka, K. **82:**79
Hoshide, S., see Katsuura, Y. **82:**147
Hsu, L.-Y., see Chou, T.-C. **84:**83
Huber, K., see Zehetgruber, M. **83:**143
Huggan, P.J., A.A. Milne, H. Bessos, A. Atkinson, W.G. Murphy. Plasma glycocalicin levels are not elevated in patients with a history of transient ischaemic event and are normal in aspirinated normal volunteers. **81:**339
Hughes, J.R., J.A. Davies, C.R.M. Prentice. The effect of different microtitre plates on the enzyme-linked immunosorbent assay (ELISA) for anticardiolipin antibodies (ACAs). **84:**217. Correction. **84:**481
Hughes, P., see Knudsen, L. **84:**45

Iacoviello, L., see Chabielska, E. **82:**69
Iguchi, A., see Naito, M. **84:**129
Iguchi, K., S. Murakami, A. Matsumoto, A. Shimizu, N. Sakuragawa. Abnormally high level of antithrombin in a case with hepatocellular carcinoma. **84:**137
Iino, M., W. Kisiel. Sphingosine-containing phospholipid vesicles support human factor VII autoactivation in the absence of tissue factor. **82:**119
Ikeda, M., J.-i. Kambayashi, S.-i. Iwamoto, N. Shinoki, T. Nakamura, K. Okahara, K. Fujitani, T. Shibuya, T. Kawasaki, M. Monden. Hemostasis activation during sclerotherapy of lower extremity varices. **82:**87
Ikeda, M., T. Onda, I. Tomita, T. Tomita. The differences in Ca^{2+}-sensitivity of protein kinase C in platelets from Wistar Kyoto rat and stroke-prone spontaneously hypertensive rat. **82:**417
Ikeda, Y., see Goto, S. **84:**351
Ikematsu, S., K. Fukutake, N. Aoki. Heterozygote for plasmin inhibitor deficiency developing hemorrhagic tendency with advancing age. **82:**129
Ilari, I., see Chiarantini, E. **82:**137
Imbault, P., F. Doutremepuich, O. Aguejouf, C. Doutremepuich. Antithrombotic effects of aspirin and LMWH in a laser-induced model of arterials and venous thrombosis. **82:**469
Imbault, P., see Belougne, E. **82:**453
Inada, M., see Kaji, T. **82:**389
Inamo, J., E. Belougne, C. Doutremepuich. Importance of photo activation of Rose Bengal for platelet activation in experimental models of photochemically induced thrombosis. **83:**229
Iomhair, M.M., S.M. Lavelle. Effect of aspirin-dipyridamole and heparin and their combination on venous thrombosis in hypercoagulable or thrombotic animals. **82:**479
Iomhair, M.M., see Lavelle, S.M. **84:**411
Iqbal, O., see Hayes, J.M. **82:**187
———, see Yang, L.H. **84:**167
Itoh, H., C. Cicala, G.J. Douglas, C.P. Page. Platelet accumulation induced by bacterial endotoxin in rats. **83:**405
Iversen, L.H., O. Thorlacius-Ussing. Short-time stability of markers of coagulation and fibrinolysis in frozen plasma. **81:**253. Correction. **82:**199
———. Markers of fibrin formation in colorectal surgery: fibrinopeptide A and soluble fibrin. **81:**569
Iversen, N., P.M. Sandset, U. Abildgaard, P.A. Torjesen. Binding of tissue factor pathway inhibitor to cultured endothelial cells—influence of glycosaminoglycans. **84:**267
Iwamoto, S.-i., see Ikeda, M. **82:**87
Iwan-Ziętek, I., see Ziętek, Z. **83:**399
Izquierdo, C., see Bal dit Sollier, C. **81:**427

Jacobsen, E.M., P.M. Sandset, F. Wisløff. [illegible] anticoagulant and a functional assay for tissue factor [illegible] hibitor (Letter to the Editors-in-Chief). **83:**339
Jacobsen, E.M., F. Wisløff. False negative screening tests for lupus anticoagulants—an unrecognized problem?. **82:**445
Jansson, U., see Henriksson, A.E. **82:**409
Jardel, C., see Bastard, J.-P. **81:**271
Jen, C.J., see Shi, G.-Y. **81:**75
Jepsson, J.-O., see Zöller, B. **83:**475
Jeske, W., see Hayes, J.M. **82:**187
Jespersen, J., see Marckmann, P. **82:**439
———, see Myrup, B. **81:**485
Johansen, H.T., see Karlsrud, T.S. **82:**265
Jollès, P., see Bal dit Sollier, C. **81:**427
Jorquera, J.I., J. Aznar, M.A. Fernández, J.M. Montoro, R. Curats, P. Casaña. A modification of the APC resistance test and its application to the study of patients on coumarin therapy. **82:**217
Jungo, M., see Steinmann, C. **81:**145
Jürgens, H., see Nowak-Göttl, U. **81:**665
Jyu-ri, K., see Kamikubo, Y.-i. **83:**161

Kaider, A., see Grubic, N. **84:**431
Kaiser, B., M. Koza, J.M. Walenga, J. Fareed. Flow cytometric

evaluation of the effect of various thrombin inhibitors on platelet activation in whole blood. **82:**257
Kaji, T., M. Inada, C. Yamamoto, Y. Fujiwara, F. Koizumi. Cyclic AMP-dependent pathway that mediates suppressive regulation of glycosaminoglycan production in cultured vascular endothelial cells. **82:**389
Kaji, T., see Fujii, N. **82:**379
Kambayashi, J.-i., N. Shinoki, T. Nakamura, H. Ariyoshi, T. Kawasaki, M. Sakon, M. Monden. Prevalence of impaired responsiveness to epinephrine in platelets among Japanese. **81:**85
Kambayashi, J.-i., see Ikeda, M. **82:**87
Kamei, S., see Kamikubo, Y.-i. **83:**161
Kamikubo, Y.-i., T. Hamuro, J.-i. Matsuda, S. Kamei, K. Jyu-ri, S. Miyamoto, A. Funatsu, H. Kato. The clearance of proteoglycan-associated human recombinant tissue factor pathway inhibitor (H-RTFPI) in rabbits: a complex formation of H-RTFPI with factor Xa promotes a clearance rate of H-RTFPI. **83:**161
Kamisue, S., see Sawamoto, Y. **83:**279
Kanazuka, M., T. Shigekiyo, N. Toibana, S. Saito. Increase in plasma thrombomodulin level in patients with vibration syndrome. **82:**51
Kaneko, H., see Rydzewski, A. **84:**445
Kang, A.H., see Chiang, T.M. **84:**399
Kang, E.S., see Chiang, T.M. **84:**399
Kaplan, C., see Galanakis, D. **81:**263
Karakoca, Y., see Özdemir, O. **84:**121
Karanikas, G., see Schmid, P. **81:**451
Kario, K., see Sakata, T. **81:**687, **82:**235
Karlsrud, T.S., L. Buø, A.O. Aasen, H.T. Johansen. Quantification of kininogens in plasma. A functional method based on the cysteine proteinase inhibitor activity. **82:**265
Kasiewski, C.J., see Bostwick, J.S. **82:**495
Katayama, Y., see Sakata, T. **81:**687, **82:**235
Kato, H., see Kamikubo, Y.-i. **83:**161
———, see Sakata, T. **81:**687, **82:**235
Kato, K., Y.A. Elsayed, M. Namoto, K. Nakagawa, K. Sueishi. Enhanced expression of tissue factor activity in the atherosclerotic aortas of cholesterol-fed rabbits. **82:**335
Katsumi, A., see Yamazaki, T. **82:**275
Katsuura, Y., T. Mochizuki, M. Tamura, S. Hoshide, M. Kiyoki, T. Nakagaki, S. Miyamoto. Species specificity of anticoagulant activity of activated human protein C. Involvement of factor V as well as protein S. **82:**147
Katsuura, Y., S. Okamoto, N. Ohno, K. Wanaka. Effects of a highly selective synthetic inhibitor of plasma kallikrein on disseminated intravascular coagulation in rats. **82:**361
Kawabata, A. 1*H*-[1,2,4]oxadiazolo[4,3-*a*]quinoxalin-1-one reverses the inhibition by sodium nitroprusside of thrombin-induced platelet aggregation in the rat (Letter to the Editors-in-Chief). **82:**543
Kawasaki, T., see Ikeda, M. **82:**87
———, see Kambayashi, J.-i. **81:**85
Kaya, S.U., see Uğurman, F. **84:**295
Kececioglu, D., see Vielhaber, H. **81:**651
Keddad, K., S.M. Razavian, Ch. Baussan, A. Abella, J. Chalas, J. Levenson, A. Simon, N. Moatti, A. Legrand. Decreased erythrocyte deformability in glycogen storage disease. **82:**159
Kehl, H.G., see Vielhaber, H. **81:**651
Kehrel, B., see Vielhaber, H. **81:**651
Kelly, K.E., see Syed, S. **84:**419
Kessler, C., R. Mitusch, Y. Guo, A. Rosengart, A. Sheikhzadeh. Embolism from the aortic arch in patients with cerebral ischemia. **84:**145
Kheiri, S.A., T.M. Fasy, H.H. Billett. Effects of H1 histones and a monoclonal autoantibody to H1 histones on clot formation *in vitro*: possible implications in the antiphospholipid syndrome. **82:**43
Khurana, U., see Dandona, P. **81:**163
Kisiel, W., see Iino, M. **82:**119
Kitazato, K., K.T. Kitazato, H. Nagase, K. Minamiguchi. DHG, a new depolymerized holothurian glycosaminoglycan, exerts an antithrombotic effect with less bleeding than unfractionated or low molecular weight heparin, in rats. **84:**111
Kitazato, K., see Minamiguchi, K. **83:**253
Kitazato, K.T., see Kitazato, K. **84:**111
———, see Minamiguchi, K. **83:**253
Kiyoki, M., see Katsuura, Y. **82:**147
Klein, S.I., see Bostwick, J.S. **82:**495
Kluft, C., see Myrup, B. **81:**485
Knöfler, R., G. Weissbach, E. Kuhlisch. Critical evaluation of the quantification of ATP release reaction in whole blood. **84:**157
Knöfler, R., see Malyszko, J. **81:**397
Knudsen, L., J.M. Hasenkam, H.H. Kure, P. Hughes, L. Bellaiche, P. Ahlburg, C. Djurhuus. Monitoring thrombin generation with prothrombin fragment 1.2 assay during cardiopulmonary bypass surgery. **84:**45
Koch, H.G., see Vielhaber, H. **81:**651
Kohlhase, B., see Nowak-Göttl, U. **81:**665
———, see Vielhaber, H. **81:**651
Koizumi, F., see Fujii, N. **82:**379
———, see Kaji, T. **82:**389
Kojima, T., see Yamazaki, T. **82:**275
Kökoğlu, E., see Süer, S. **83:**77
Kolpakov, V., see Chabielska, E. **82:**69
Kolstø, A.-B., see Camerer, E. **81:**1
Köseoğlu, V., see Tanındı, Ş. **81:**471
Kotschy, M., see Ziętek, Z. **83:**399
Koza, M., see Kaiser, B. **82:**257
Krailadsiri, P., J. Seghatchian. Negatively charged leucocyte filter significantly enhances kallikrein and thrombin-like activities of platelet concentrates. **83:**469
Kramer, G., see Fischer, B.E. **84:**55
Kramer, W.S., see Gralnick, H.R. **81:**113
Kretz, J.-G., N. Chakfe, M.-L. Wiesel, L. Grunebaum, V. Zamboni, E. Palazzini, J.-P. Cazenave. The treatment of deep vein thrombosis with continuous intravenous low-molecular-weight dermatan sulphate (Desmin). A pilot study. **84:**391
Kritz, H., see Schmid, P. **81:**451
———, see Sinzinger, H. **84:**475
Krutzsch, H., see Gralnick, H.R. **81:**113
Kuhlisch, E., see Knöfler, R. **84:**157
Kume, S., see Qi, R. **81:**43
———, see Satoh, K. **81:**515
Kure, H.H., see Knudsen, L. **84:**45
Kürekçi, A.E., see Tanındı, Ş. **81:**471
Kurota, K., see Qi, R. **81:**43
Kurtaran, A., see Veitl, M. **82:**399
Kushimoto, S., K. Okajima, M. Uchiba, K. Murakami, H. Okabe, K. Takatsuki. Pulmonary vascular injury induced by hemorrhagic shock is mediated by P-selectin in rats. **82:**97
Küsters, B., see Storck, J. **84:**463

Lacroix, K.A., C. Bean, L. Box, K. Wagner. A study of the fibrinolytic response in healthy men and women following a brief exposure to venous occlusion. **81:**133
Lämmle, B., see Steinmann, C. **81:**145
Lamponi, S., see Magnani, A. **81:**383
Laporte, A., see Roussi, J. **81:**297
Laporte-Simitsidis, S., see Tardy, B. **83:**153
Lassen, M.R., see Rahr, H.B. **81:**607
Lasser, R., see Reininger, C.B. **81:**641

Lassila, R., see Peltonen, S. **82:**369, 459
Lavelle, S.M., M.M. Iomhair. The quantitative reduction by acute-dose warfarin of venous thrombosis in normal and hyperthrombotic rats. **84:**411
Lavelle, S.M., see Iomhair, M.M. **82:**479
Lavenne-Pardonge, E., see Schlit, A.-F. **84:**203
Leadley, R.J., Jr., see Bostwick, J.S. **82:**495
Lee, T.K., N. Bangalore, W. Velander, W.N. Drohan, H. Lubon. Activation of recombinant human protein C. **82:**225
Legrand, A., see Keddad, K. **82:**159
Leksell, H., see Zöller, B. **83:**475
Lentz, S.R., see Newell, A.A. **84:**373
Lepäntalo, M., see Peltonen, S. **82:**369
Leray, C., see Pöschl, J.M.B. **81:**283
Leroy-Matheron, C., see Gouault-Heilmann. **82:**281
Leskopf, W., see Vogel, G. **81:**241
Levenson, J., see Keddad, K. **82:**159
Lewandowski, K., W. Elikowski, Z. Turowiecka, M. Zozulińska, L. Przybył, K. Zawilska. Low molecular weight heparin and the heparin mobilisable pool of platelet factor 4 are reduced in young survivors of myocardial infarction. **81:**615
Lewandowski, K., Z. Turowiecka, J. Puszczewicz, S. Mackiewicz, K. Zawilska. Antiphospholipid antibodies and disturbances of phospholipid dependent coagulation tests in patients with systemic sclerosis and severe peripheral ischaemia (Letter to the Editors-in-Chief). **81:**693
Li, P., see Xia, L. **81:**477
Li, X.-B., see Wong, K. **81:**219
Lin, M.T., see Shi, G.-Y. **81:**75
Lind, S.E., see Cloherty, T. **83:**137
Lindblad, B., see Holst, J. **81:**461
Linderkamp, O., see Pöschl, J.M.B. **81:**283
Liotta, A.A., see Boddi, M. **82:**207
———, see Chiarantini, E. **82:**137
———, see Comeglio, P. **84:**199
Littlewood, T.J., see Denson, K.W.E. **81:**151
Liu, Y., see Xia, L. **81:**477
Liverani, L., see Mascellani, G. **84:**21
Lluch, I., see Martínez, M. **83:**375
Lo, S.K., see Simantov, R. **84:**361
Lorentzen, B., see Andersson, T. **82:**109
Love, J., see Dandona, P. **81:**163
Lowe, K.C., see Edwards, C.M. **81:**511
Lubbers, N.L., see Burke, S.E. **83:**421
Lubon, H., see Lee, T.K. **82:**225
Lucena, M.I., see González-Correa, J.A. **81:**367
Lunec, J., see Casey, M.C. **84:**223
Lyle, V.A., see Finch, C.N. **81:**679

Machin, S.J., see Cardigan, R.A. **84:**237
Maciejewski, J.P., N.S. Young, M. Yu, S.M. Anderson, E.M. Sloand. Analysis of the expression of glycosylphosphatidylinositol anchored proteins on platelets from patients with paroxysmal nocturnal hemoglobinuria. **83:**433
Mackie, I.J., see Cardigan, R.A. **84:**237
Mackiewicz, S., see Lewandowski, K. **81:**693
Magnani, A., A. Albanese, S. Lamponi, R. Barbucci. Blood-interaction performance of differently sulphated hyaluronic acids. **81:**383
Makris, P.E., see Gerotziafas, G.T. **81:**491
Malyszko, J., J.S. Malyszko, D. Pawlak, K. Pawlak, W. Buczko, M. Mysliwiec. Hemostasis, platelet function and serotonin in acute and chronic renal failure. **83:**351
Malyszko, J., T. Urano, R. Knöfler, Y. Takada, A. Takada. Effects of short-term treatment with mevalotin on platelet aggregation, fibrinolysis, peripheral serotonergic system and serum lipids in Japanese monkeys. **81:**397
Malyszko, J., see Pawlak, D. **83:**189
Malyszko, J.S., see Malyszko, J. **83:**351
———, see Pawlak, D. **83:**189
Mameli, G., see Barcellona, D. **81:**403
Mammen, E.F. Walter H. Seegers 1910–1996 (Obituary). **84:**303
Mannucci, P.M., see Bottasso, B. **81:**345
Manotti, C., see Dettori, A.G. **83:**103
Marckmann, P., P. Nawroth, P. Wahl, J. Jespersen. Diet, gender, and plasma thrombomodulin. **82:**439
Mari, D., see Bottasso, B. **81:**345
Mariani, G., see Coniglio, M. **83:**183
Marongiu, F., G. Biondi, D. Barcellona, M.L. Vannini, A. Balestrieri. The old manual tilt tube thrombotest: still useful in the management of oral anticoagulants?. **84:**379
Marongiu, F., see Barcellona, D. **81:**403
Martí, R., see Martínez, M. **83:**375
Martínez, M., A. Vayá, R. Martí, L. Gil, I. Lluch, R. Carmena, J. Aznar. Erythrocyte membrane cholesterol/phospholipid changes and hemorheological modifications in familial hypercholesterolemia treated with lovastatin. **83:**375
Martini, F., A. Zuppiroli, A.M. Gori, E. Chiarantini, S. Fedi, D. Prisco, A.P. Cellai, V. Boddi, R. Abbate, A. Dolara, G.F. Gensini. Platelet and blood clotting activation in patients with mitral valve prolapse. **83:**299
Mascellani, G., L. Liverani, B. Parma, G.L. Bergonzini, P. Bianchini. Active site for heparin cofactor II in low molecular mass dermatan sulfate. Contribution to the antithrombotic activity of fractions with high affinity for heparin cofactor II. **84:**21
Massucco, P., see Anfossi, G. **82:**57
Matsuda, J.-i., see Kamikubo, Y.-i. **83:**161
Matsumoto, A., see Iguchi, K. **84:**137
Matsuo, N., see Shinya, H. **81:**195
Matsuyama, T., see Sakata, T. **81:**687, **82:**235
Mattiello, L., see Anfossi, G. **82:**57
May, J.A., see Edwards, C.M. **81:**511
Mazurier, C., see de Romeuf, C. **83:**287
McAndrew, P.E., J.T. Brandt, D.K. Pearl, T.W. Prior. The incidence of the gene for thermolabile methylene tetrahydrofolate reductase in African Americans. **83:**195
McGill, A., see Bessos, H. **84:**367
McGuiness, J.A., see Selley, M.L. **83:**449
McIntyre, J.A., see Sugi, T. **84:**97
McKeown, L.P., see Gralnick, H.R. **81:**113
McLoughlin, P., see Boutcher, P.A. **81:**231
Mecacci, F., see Boddi, M. **82:**207
———, see Comeglio, P. **84:**199
Meehan, A., see Melton, L.G. **83:**265
Mello, G., see Boddi, M. **82:**207
———, see Comeglio, P. **84:**199
Melton, L.G., G.J. Dehmer, D.A. Tate, K.M. Muga, A. Meehan, D.A. Gabriel. Variable influence of heparin and contrast agents on platelet function as assessed by the *in vitro* bleeding time. **83:**265
Mérida, F., see De La Cruz, J.P. **81:**327
Mezzano, D., see Aranda, E. **84:**67
Micheli, S., see Gensini, G.F. **84:**1
Mieszczak, C., K. Winther. Does warfarin enhance platelet activity?. **84:**285
Mikkola, T., see Turunen, P. **81:**635
Miller, J.L., see Finch, C.N. **81:**679
Millet, J., M. Vaillot, J. Theveniaux, N.L. Brown. Experimental venous thrombosis induced by homologous serum in the rat. **81:**497

Milne, A.A., see Huggan, P.J. **81:**339
Minamiguchi, K., H. Nagase, K.T. Kitazato, K. Kitazato. Interaction of a new depolymerized holothurian glycosaminoglycan with proteins in human plasma. **83:**253
Minamiguchi, K., see Kitazato, K. **84:**111
Mitchell, V., see Casey, M.C. **84:**223
Mitterer, A., see Fischer, B.E. **81:**157, **84:**55
Mitusch, R., see Kessler, C. **84:**145
Miyamoto, S., see Kamikubo, Y.-i. **83:**161
———, see Katsuura, Y. **82:**147
Miyata, T., see Sakata, T. **81:**687, **82:**235
Moatti, N., see Keddad, K. **82:**159
Mochizuki, M., Y. Takada, T. Urano, N. Nagai, T. Nakano, K. Nakajima, A. Takada. The *in vitro* effects of chylomicron remnant and very low density lipoprotein remnant on platelet aggregation in blood obtained from healthy persons. **81:**583
Mochizuki, T., see Katsuura, Y. **82:**147
Modzrewska, R., see Coniglio, M. **83:**183
Monden, M., see Ikeda, M. **82:**87
———, see Kambayashi, J.-i. **81:**85
Monroe, D.M., see Sumner, W.T. **81:**533
Montoro, J.M., see Jorquera, J.I. **82:**217
Moreno, A., see De La Cruz, J.P. **81:**327
Moriau, M., see Schlit, A.-F. **84:**203
Morrical, D., see Peng, F. **83:**243
Morser, J., see Öhlin, A.-K. **82:**313
Morys-Wortmann, C., see Storck, J. **84:**463
Motoyama, Y., see Aoki, T. **81:**439
Mousa, S., see Dandona, P. **81:**163
Mowinckel, M.-C., see Andersson, T. **82:**109
Muga, K.M., see Melton, L.G. **83:**265
Mularoni, E., see Anfossi, G. **82:**57
Mundt, W., see Fischer, B.E. **84:**55
Muntean, W., see Edlinger, G. **83:**403
Murakami, K., see Kushimoto, S. **82:**97
Murakami, S., see Iguchi, K. **84:**137
Murphy, P.T., see Casey, M.C. **84:**223
Murphy, W.G., see Bessos, H. **84:**367
———, see Huggan, P.J. **81:**339
Myrup, B., M. de Maat, P. Rossing, J. Gram, C. Kluft, J. Jespersen. Elevated fibrinogen and the relation to acute phase response in diabetic nephropathy. **81:**485
Mysliwiec, J., A. Azzadin, E. Chabielska, A. Takada, M. Mysliwiec, W. Buczko. The effect of tacrolimus (FK506) and cyclosporin A (CyA) on peripheral serotonergic mechanisms in uremic rats. **83:**175
Mysliwiec, M., see Malyszko, J. **83:**351
———, see Mysliwiec, J. **83:**175
———, see Pawlak, D. **83:**189

Nagai, N., see Mochizuki, M. **81:**583
Nagase, H., see Kitazato, K. **84:**111
———, see Minamiguchi, K. **83:**253
Nair, C.H., see van Gelder, J.M. **82:**33
Naito, M., H. Nomura, A. Iguchi. Migration of cultured vascular smooth muscle cells into non-crosslinked fibrin gels. **84:**129
Naito, T., see Wanaka, K. **82:**79
Nakagaki, T., see Katsuura, Y. **82:**147
Nakagawa, K., see Kato, K. **82:**335
Nakai, H., see Sawamoto, Y. **83:**279
Nakajima, K., see Mochizuki, M. **81:**583
Nakamura, T., see Ikeda, M. **82:**87
———, see Kambayashi, J.-i. **81:**85
Nakano, T., see Mochizuki, M. **81:**583
Namoto, M., see Kato, K. **82:**335
Naso, A., see Cella, G. **81:**671
Nastasi, M., see Cignarella, A. **84:**311
Nawroth, P., see Marckmann, P. **82:**439
Neumann, F.-J., see Gawaz, M. **83:**341
Neumann, I., see Sinzinger, H. **84:**475
Newell, A.A., T.J. Raife, S.R. Lentz. Interference in protein C activation assays from endogenous serpins in mammalian host cells. **84:**373
Nguan, O., see Wong, P.C. **83:**117
Niiya, K., see Ozawa, T. **81:**595
Nikandrov, N.N., see Pyzhova, N.S. **82:**303
Nikandrov, V.N., see Pyzhova, N.S. **82:**303
Nilsson, Å., see Xu, N. **81:**203
Nilsson, J.-E., see Zöller, B. **83:**475
Nilsson, T.K., see Henriksson, A.E. **82:**409
Nomura, H., see Naito, M. **84:**129
Norberg, K., see Salte, R. **83:**389
Nordfang, O., see Holst, J. **81:**461
Norlund, L., see Zöller, B. **83:**475
Norris, L.A., M. Devitt, J. Bonnar. The role of thromboxane A_2 in increased whole blood platelet aggregation in oral contraceptive users. **81:**407
Novinger, M.S., see Phillips, D.J. **81:**307
Nowak-Göttl, U., B. Kohlhase, H. Vielhaber, I. Aschka, R. Schneppenheim, H. Jürgens. APC resistance in neonates and infants: adjustment of the APTT-based method. **81:**665
Nowak-Göttl, U., see Vielhaber, H. **81:**651
Nowotarski, M., see Cierniewski, C.S. **82:**349
Nowotny, C., see Ulm, M.R. **83:**237
Nuovo, G., see Galanakis, D. **81:**263
Nurden, A.T., see Pasquet, J.-M. **82:**509

O'Brien, J.R. Angiodysplasia, haemostasis and capillaries. A hypothesis (Letter to the Editors-in-Chief). **84:**385
Obwegeser, R., see Ulm, M.R. **83:**237
Ødegaard, O.R., see Salte, R. **83:**389
O'Grady, J., see Pirich, C. **81:**213
O'Grady, J., see Sinzinger, H. **82:**291, **84:**475
Öhlin, A.-K., J. Morser, H. Öhlin. Soluble thrombomodulin antigen in plasma is increased in patients with acute myocardial infarction treated with thrombolytic therapy. **82:**313
Öhlin, A.-K., see Xu, N. **81:**203
Öhlin, H., see Öhlin, A.-K. **82:**313
Ohno, N., see Katsuura, Y. **82:**361
———, see Wanaka, K. **82:**79
Okabe, H., see Kushimoto, S. **82:**97
Okada, Y., see Wanaka, K. **82:**79
Okahara, K., see Ikeda, M. **82:**87
Okajima, K., see Kushimoto, S. **82:**97
Okamoto, S., see Katsuura, Y. **82:**361
———, see Wanaka, K. **82:**79
Okamoto, U., see Wanaka, K. **82:**79
Olsson, P. Birger Blombäck: an appreciation on his seventieth birthday. **82:**287
Onda, T., see Ikeda, M. **82:**417
Önde, G., see Uğurman, F. **84:**295
O'Regan, R.G., see Boutcher, P.A. **81:**231
Örning, L., see Rønning, H.F. **84:**73
———, see Stephens, R.W. **84:**453
Örsel, O., see Uğurman, F. **84:**295
Østergaard, P.B., see Holst, J. **81:**461
Owen, W.G., see Bichler, J. **84:**289
Owens, M.R., S. Holme. Aurin tricarboxylic acid inhibits adhesion of platelets to subendothelium. **81:**177
Ozaki, Y., see Qi, R. **81:**43

———, see Satoh, K. **81:**515
Ozawa, T., K. Niiya, N. Sakuragawa. Absence of factor V Leiden in the Japanese (Letter to the Editors-in-Chief). **81:**595
Özcan, O., see Tanındı, Ş. **81:**471
Özdemir, O., S. Emri, Y. Karakoca, N. Sayınalp, H. Akay, S. Dündar, İ. Barış. Fibrinolytic system in plasma and pleural fluid in malignant pleural mesothelioma. **84:**121

Paczulski, R., see Ziętek, Z. **83:**399
Page, C.P., see Itoh, H. **83:**405
Palazzini, E., see Dettori, A.G. **83:**103
———, see Kretz, J.-G. **84:**391
Paoletti, G., see Anfossi, G. **82:**57
Parma, B., see Mascellani, G. **84:**21
Parretti, E., see Boddi, M. **82:**207
———, see Comeglio, P. **84:**199
Pasquet, J.-M., F. Toti, A.T. Nurden, J. Dachary-Prigent. Procoagulant activity and active calpain in platelet-derived microparticles. **82:**509
Pawlak, D., J. Malyszko, J.S. Malyszko, K. Pawlak, W. Buczko, M. Mysliwiec. Peripheral serotonergic system in uremia. **83:**189
Pawlak, D., see Malyszko, J. **83:**351
Pawlak, K., see Malyszko, J. **83:**351
———, see Pawlak, D. **83:**189
Pearl, D.K., see McAndrew, P.E. **83:**195
Peltonen, S., R. Lassila, J. Heikkilä. Activation of coagulation and fibrinolysis despite heparinization during successful elective coronary angioplasty. **82:**459
Peltonen, S., R. Lassila, M. Lepäntalo. Increased circulating plasminogen activator inhibitor-1 in patients with patent femorodistal venous bypass. **82:**369
Peng, F., D. Triplett, L. Barna. Direct PCR of leukocytes treated with microwave irradiation to detect factor V Leiden mutation. **82:**193
Peng, F., D. Triplett, L. Barna, D. Morrical. Pulmonary embolism and premature labor in a patient with both factor V Leiden mutation and methylenetetrahydrofolate reductase gene C677T mutation. **83:**243
Peng, F., see Hoagland, L.E. **83:**363
Pereira, J., see Aranda, E. **84:**67
Perrone, M.H., see Bostwick, J.S. **82:**495
Pescador, R., see Fisher, J. **81:**55
Peskar, B.A., see Schmid, P. **81:**451
———, see Sinzinger, H. **84:**475
Peternel, P., see Grubic, N. **84:**431
Pettirossi, G., see Basili, S. **84:**279
Pfaffenbach, G.M., J.A. Bussel, P. Rubinstein. A rapid genotype assay for Pl^A haplotypes. **81:**353
Phillips, D.J., M.S. Novinger, B.L. Evatt, W.C. Hooper. TNF-α suppresses IL-1α and IL-6 upregulation of C4b-binding protein in HepG-2 hepatoma cells. **81:**307
Phillips, D.J., see Benson, J.M. **83:**87
———, see Hooper, W.C. **81:**315
Pich, I., C. de Castellarnau. Plasma stimulation of prostacyclin production by rat smooth muscle cells requires previous induction of phospholipase activity. **82:**323
Pidlich, J., see Ulm, M.R. **83:**237
Pietrucha, T., see Golański, J. **83:**199
Pignaud, G., see Bal dit Sollier, C. **81:**427
———, see Roussi, J. **81:**297
Pinot, A., see Gralnick, H.R. **81:**113
Piretto, V., see Anfossi, G. **82:**57
Pirich, C., Y. Efthimiou, J. O'Grady, C. Zielinski, H. Sinzinger. Apolipoprotein A and biological half-life of prostaglandin I_2 in HIV-1 infection. **81:**213
Pirich, C., see Schmid, P. **81:**451
———, see Sinzinger, H. **82:**291
Platania, A., see Coniglio, M. **83:**183
Ploeckinger, B., see Ulm, M.R. **83:**237
Pluskota, E., see Cierniewski, C.S. **82:**349
Pokhilko, A.V., see Zarnitsina, V.I. **84:**225, 333
Porquet, D., see Bastard, J.-P. **81:**271
Porta, R., see Fisher, J. **81:**55
Pöschl, J.M.B., C. Leray, R. Groscolas, P. Ruef, O. Linderkamp. Dietary docosahexaenoic acid improves red blood cell deformability in rats. **81:**283
Prentice, C.R.M., see Hughes, J.R. **84:**217
Prieto, C., see Aranda, E. **84:**67
Prior, T.W., see McAndrew, P.E. **83:**195
Prisco, D., see Boddi, M. **82:**207
———, see Chiarantini, E. **82:**137
———, see Comeglio, P. **84:**199
———, see Gensini, G.F. **84:**1
———, see Martini, F. **83:**299
Prydz, H., see Camerer, E. **81:**1
Przybył, L., see Lewandowski, K. **81:**615
Pueyo, C., J.J. Badimon, T. Royo, L.P. Feigen, L. Badimon. A mimetic of the RGDF-peptide [arginine-glycine-aspartic acid-phenylalanine] blocks aggregation and flow-induced platelet deposition on severely injured stenotic arterial wall. Effects on different animal models and in humans. **81:**101
Puglisi, L., see Cignarella, A. **84:**311
Pulcinelli, F.M., see Basili, S. **84:**279
Puszczewicz, J., see Lewandowski, K. **81:**693
Pyzhova, N.S., V.N. Nikandrov, N.N. Nikandrov. Effect of active oxygen species scavengers on fibrinolytic activity of some proteinases. **82:**303

Qi, R., Y. Ozaki, K. Satoh, K. Kurota, N. Asazuma, Y. Yatomi, S. Kume. Quantitative measurement of various 5-HT receptor antagonists on platelet activation induced by serotonin. **81:**43
Qi, R., see Satoh, K. **81:**515

Racanelli, A., see Wong, P.C. **83:**117
Rahr, H.B., D. Danielsen, B.S. Andersen, L.C. Borris, M.R. Lassen. Poor correlation between soluble fibrin concentrations measured by two commercially available immunoassays. **81:**607
Raife, T.J., see Newell, A.A. **84:**373
Rampin, E., see Cella, G. **81:**671
Raneli, G., see Avellone, G. **81:**277
Rao, G.H.R., see White, J.G. **84:**253
Rao, L.V.M., see Zivelin, A. **82:**429
Rapaport, S.I., see Zivelin, A. **82:**429
Rascle, F., see Tardy, B. **83:**153
Raut, S., P.J. Gaffney. Interaction of heparin with fibrinogen using surface plasmon resonance technology: investigation of heparin binding site on fibrinogen. **81:**503
Raut, S., see Boutcher, P.A. **81:**231
Rawlins, P., see Hooper, W.C. **81:**577
Razavian, S.M., see Keddad, K. **82:**159
Reed, S.V., see Denson, K.W.E. **81:**151
Reininger, A., see Gawaz, M. **83:**341
Reininger, A.J., see Reininger, C.B. **82:**523
Reininger, C.B., J. Graf, A.J. Reininger, M. Spannagl, B. Steckmeier, L. Schweiberer. Increased platelet and coagulatory activity indicate ongoing thrombogenesis in peripheral arterial disease. **82:**523
Reininger, C.B., A. Greinacher, J. Graf, R. Lasser, B. Steckmeier,

L. Schweiberer. Platelets of patients with peripheral arterial disease are hypersensitive to heparin. **81:**641
Reininger, I.M., see Burke, S.E. **83:**421
Reiter, M., see Fischer, B.E. **84:**55
Ribeiro, M.J.A., see Hooper, W.C. **81:**577
Risøen, U.C., see Rønning, H.F. **84:**73
Rivers, R.P.A., see Stephens, A.C. **81:**545
Rønning, H.F., U.C. Risøen, L. Örning, K. Sletten, K.S. Sakariassen. Synthetic peptide analogs of tissue factor and factor VII which inhibit factor Xa formation by the tissue factor/factor VIIa complex. **84:**73
Rosén, U., see Zöller, B. **83:**475
Rosengart, A., see Kessler, C. **84:**145
Rossing, P., see Myrup, B. **81:**485
Rota, S., P.D. Flynn, N.J. Wareham, T.P. Baglin, C.D. Byrne. Is platelet phospholipid-dependent thrombin generation altered by acute myocardial infarction or aspirin?. **83:**329
Rotolo, G., see Avellone, G. **81:**277
Roussi, J., P. André, M. Samama, G. Pignaud, M. Bonneau, A. Laporte, L. Drouet. Platelet functions and haemostasis parameters in pigs: absence of side effects of a procedure of general anaesthesia. **81:**297
Royo, T., see Pueyo, C. **81:**101
Ruan, C., see Xia, L. **81:**477
Rubinstein, P., see Pfaffenbach, G.M. **81:**353
Ruef, P., see Pöschl, J.M.B. **81:**283
Rydzewski, A., T. Urano, T. Hachiya, H. Kaneko, S. Baba, Y. Takada, A. Takada. The effect of a $5HT_2$ receptor antagonist sarpogrelate (MCI-9042) treatment on platelet function in Buerger's disease. **84:**445

Sabatino, R.D., see Bostwick, J.S. **82:**495
Sahud, M., see Drasin, T. **84:**179
Saito, H., see Yamazaki, T. **82:**275
Saito, S., see Kanazuka, M. **82:**51
Sakariassen, K.S., see Rønning, H.F. **84:**73
———, see Stephens, R.W. **84:**453
Sakata, T., Y. Goto, K. Kario, Y. Katayama, T. Matsuyama, H. Kato, T. Miyata. Recurrent restenosis after percutaneous transluminal coronary angioplasty in a patient with congenital protein C deficiency and high activated factor VII level. **81:**687
Sakata, T., K. Kario, Y. Katayama, T. Matsuyama, H. Kato, T. Miyata. Clinical significance of activated protein C resistance as a potential marker for hypercoagulable state. **82:**235
Sakon, M., see Kambayashi, J.-i. **81:**85
Sakuragawa, N., see Iguchi, K. **84:**137
———, see Ozawa, T. **81:**595
Salmon, D.M. Optimisation of platelet aggregometry utilising microtitreplate technology and integrated software. **84:**213
Salmon, J.E., see Simantov, R. **84:**361
Salte, R., K. Norberg, O.R. Ødegaard. Evidence of a protein C-like anticoagulant system in bony fish. **83:**389. Correction. **84:**300
Samama, M., see Roussi, J. **81:**297
Samama, M.M., see Gerotziafas, G.T. **81:**491
———, see Tardy, B. **83:**153
Sammaritano, L.R., see Simantov, R. **84:**361
Samurkaşoğlu, B., see Uğurman, F. **84:**295
Sánchez de la Cuesta, F., see De La Cruz, J.P. **81:**327
———, see González-Correa, J.A. **81:**367
Sandset, P.M., see Iversen, N. **84:**267
———, see Jacobsen, E.M. **83:**339
Santoro, N., see Bottasso, B. **81:**345
Satoh, K., Y. Ozaki, R. Qi, L. Yang, N. Asazuma, Y. Yatomi, S. Kume. Factors that affect the size of platelet aggregates in epinephrine-induced activation: a study using the particle counting method based upon light scattering. **81:**515
Satoh, K., see Qi, R. **81:**43
Sawamoto, Y., M. Shima, M. Yamamoto, S. Kamisue, H. Nakai, I. Tanaka, K. Hayashi, J.C. Giddings, A. Yoshioka. Measurement of anti-factor IX IgG subclasses in haemophilia B patients who developed inhibitors with episodes of allergic reactions to factor IX concentrates. **83:**279
Sayınalp, N., see Özdemir, O. **84:**121
Sbarai, A., see Cella, G. **81:**671
Scharrer, I., see Galanakis, D. **81:**263
Schlit, A.-F., C. Col-De Beys, M. Moriau, E. Lavenne-Pardonge. Acquired activated protein C resistance in pregnancy. **84:**203
Schmid, P., G. Karanikas, H. Kritz, C. Pirich, Y. Stamatopoulos, B.A. Peskar, H. Sinzinger. Passive smoking and platelet thromboxane. **81:**451
Schneppenheim, R., see Nowak-Göttl, U. **81:**665
Schumacher, W.A., C.L. Heran, T.E. Steinbacher. Sensitivity of experimental venous and arterial thrombosis and bleeding to ancrod-induced defibrinogenation. **81:**187
Schweiberer, L., see Reininger, C.B. **81:**641, **82:**523
Seghatchian, J., see Bessos, H. **84:**367
———, see Krailadsiri, P. **83:**469
Seki, J., see Aoki, T. **81:**439
Selley, M.L., J.A. McGuiness, N.G. Ardlie. The effect of cholesterol oxidation products on human platelet aggregation. **83:**449
Senzaki, K., see Aoki, T. **81:**439
Sepúlveda, S., see Aranda, E. **84:**67
Sheffield, W.P., see Syed, S. **84:**419
Sheikhzadeh, A., see Kessler, C. **84:**145
Shi, G.-Y., S.-J. Wang, B.-I. Chang, C.-F. Tasi, M.T. Lin, W.-C. Chang, L.-Y.C. Wing, C.J. Jen, H.-L. Wu. Regulation of plasminogen activator inhibitor activity by plasmin in endothelial cells. **81:**75
Shibuya, T., see Ikeda, M. **82:**87
Shigekiyo, T., see Kanazuka, M. **82:**51
Shima, M., see Sawamoto, Y. **83:**279
Shimizu, A., see Iguchi, K. **84:**137
Shinoki, N., see Ikeda, M. **82:**87
———, see Kambayashi, J.-i. **81:**85
Shinya, H., N. Matsuo, N. Takeyama, T. Tanaka. Hyperammonemia inhibits platelet aggregation in rats. **81:**195
Siegbahn, A., see Ernofsson, M. **83:**307
Sigurdardottir, O., see Valen, G. **83:**321
Silva, V., see Hooper, W.C. **81:**577
Silverstein, R.L., see Simantov, R. **84:**361
Simantov, R., S.K. Lo, J.E. Salmon, L.R. Sammaritano, R.L. Silverstein. Factor V Leiden increases the risk of thrombosis in patients with antiphospholipid antibodies. **84:**361
Simon, A., see Keddad, K. **82:**159
Sinzinger, H., C. Pirich, J. Bednar, J. O'Grady. Ex-vivo and in-vivo platelet function in patients with severe hypercholesterolemia undergoing LDL-apheresis. **82:**291
Sinzinger, H., M.R. Ulm, I. Neumann, H. Kritz, J. O'Grady, B.A. Peskar. The prostacyclin stimulating plasma factor activity improves thromboresistance only if vascular PGI_2-production is intact. **84:**475
Sinzinger, H., see Pirich, C. **81:**213
———, see Schmid, P. **81:**451
———, see Ulm, M.R. **83:**237
Şipit, T., see Uğurman, F. **84:**295
Skjønsberg, O.H., see Bach-Gansmo, E.T. **82:**177
Skrzypek, E., S.C. Straley. Interaction between *Yersinia pestis* YopM protein and human α-thrombin. **84:**33
Sletten, K., see Rønning, H.F. **84:**73

Sloand, E.M., see Maciejewski, J.P. **83:**433
Smeets, E.F., P. Comfurius, E.M. Bevers, R.F.A. Zwaal. Contribution of different phospholipid classes to the prothrombin converting capacity of sonicated lipid vesicles. **81:**419
Sönmez, H., see Süer, S. **83:**77
Spannagl, M., see Reininger, C.B. **82:**523
———, see Vogel, G. **81:**241
Spitzer, S., see Galanakis, D. **81:**263
Stafford, D.W., see Cheung, W.-F. **81:**65
Stamatopoulos, Y., see Schmid, P. **81:**451
Steckmeier, B., see Reininger, C.B. **81:**641, **82:**523
Stegnar, M., see Grubic, N. **84:**431
Steinbacher, T.E., see Schumacher, W.A. **81:**187
Steinmann, C., M. Jungo, E.A. Beck, B. Lämmle, M. Furlan. Fibrinogen Claro—another dysfunctional fibrinogen variant with γ 275 arginine → histidine substitution. **81:**145. Correction. **82:**107
Stephens, A.C., R.Q.H. Zheng, R.P.A. Rivers. Co-localization of tissue factor protein and its mRNA in human blood monocytes. **81:**545
Stephens, R.W., L. Örning, H. Stormorken, M.J.A.G. Hamers, L. Balle Petersen, K.S. Sakariassen. Characterisation of cell-surface procoagulant activities using a microcarrier model. **84:**453
Storck, J., B. Küsters, M. Vahland, C. Morys-Wortmann, E.R. Zimmermann. Trypsin induced von Willebrand factor release from human endothelial cells is mediated by PAR-2 activation. **84:**463
Storck, J., E.R. Zimmermann. Regulation of the thrombin receptor response in human endothelial cells. **81:**121
Stormorken, H., see Stephens, R.W. **84:**453
Straley, S.C., see Skrzypek, E. **84:**33
Strauss, W.E., see Cella, G. **81:**671
Strouse, R.J., J.L. Daniel. The Dami cell possesses the platelet collagen receptor VLA-2, but does not mobilize calcium. **82:**485
Sueishi, K., see Kato, K. **82:**335
Süer, S., T. Ulutin, H. Sönmez, E. Kökoğlu, N. Üçışık, Ç. Bayram, G. Sultuybek. Plasma Lp(a) and t-PA-PAI-1 complex levels in coronary heart disease. **83:**77
Sugi, T., J.A. McIntyre. Autoantibodies to kininogen-phosphatidylethanolamine complexes augment thrombin-induced platelet aggregation. **84:**97
Sugiura, I., see Yamazaki, T. **82:**275
Sugo, T., see Cheung, W.-F. **81:**65
Sultuybek, G., see Süer, S. **83:**77
Sumner, W.T., D.M. Monroe, M. Hoffman. Variability in platelet procoagulant activity in healthy volunteers. **81:**533
Syed, S., K.E. Kelly, W.P. Sheffield. Inhibition of thrombin by hirudin genetically fused to wild-type or mutant antithrombin. **84:**419

Takada, A., see Malyszko, J. **81:**397
———, see Mochizuki, M. **81:**583
———, see Mysliwiec, J. **83:**175
———, see Rydzewski, A. **84:**445
Takada, Y., see Malyszko, J. **81:**397
———, see Mochizuki, M. **81:**583
———, see Rydzewski, A. **84:**445
Takahashi, E., see Goto, S. **84:**351
Takamatsu, J., see Yamazaki, T. **82:**275
Takamiya, O., A. Yoshioka. Factor VII binding to tissue factor in plasma from warfarin-treated individuals. **81:**657
Takasugi, H., see Aoki, T. **81:**439
Takatsuki, K., see Kushimoto, S. **82:**97
Takeyama, N., see Shinya, H. **81:**195
Tamura, M., see Katsuura, Y. **82:**147
Tanaka, A., see Aoki, T. **81:**439
Tanaka, I., see Sawamoto, Y. **83:**279
Tanaka, T., see Shinya, H. **81:**195
Tandy, N., see Bessos, H. **84:**367
Tanındı, Ş., R. Akın, V. Köseoğlu, A.E. Kürekçi, E. Gökçay, O. Özcan. The platelet aggregation in children with epilepsy receiving valproic acid. **81:**471
Tardy, B., B. Tardy-Poncet, L. Bara, S. Laporte-Simitsidis, F. Rascle, M.M. Samama, D. Guyotat, J.C. Bertrand. Effects of long travels in sitting position in elderly volunteers on biological markers of coagulation activation and fibrinolysis. **83:**153
Tardy-Poncet, B., see Tardy, B. **83:**153
Tasi, C.-F., see Shi, G.-Y. **81:**75
Tate, D.A., see Melton, L.G. **83:**265
Theveniaux, J., see Millet, J. **81:**497
Thorlacius-Ussing, O., see Iversen, L.H. **81:**253, 569
Thusu, K., see Dandona, P. **81:**163
Toibana, N., see Kanazuka, M. **82:**51
Tomita, I., see Ikeda, M. **82:**417
Tomita, T., see Ikeda, M. **82:**417
Tonelli, F., see Chiarantini, E. **82:**137
Torjesen, P.A., see Iversen, N. **84:**267
Toti, F., see Pasquet, J.-M. **82:**509
Triplett, D., see Peng, F. **82:**193, **83:**243
Triplett, D.A., see Hoagland, L.E. **83:**363
Trovati, M., see Anfossi, G. **82:**57
Tsuda, Y., see Wanaka, K. **82:**79
Tsuzuki, S., see Yamazaki, T. **82:**275
Turowiecka, Z., see Lewandowski, K. **81:**615, 693
Turunen, P., T. Mikkola, O. Ylikorkala, L. Viinikka. Hirudin stimulates prostacyclin but not endothelin-1 production in cultured human vascular endothelial cells. **81:**635

Uchiba, M., see Kushimoto, S. **82:**97
Üçışık, N., see Süer, S. **83:**77
Uğurman, F., G. Önde, S.U. Kaya, T. Şipit, B. Samurkaşoğlu, O. Örsel. Heparin appears to have no significant effect on the blood gas levels in patients with COPD (Letter to the Editors-in-Chief). **84:**295
Ulm, M.R., R. Obwegeser, B. Ploeckinger, C. Nowotny, J. Pidlich, H. Sinzinger. A case of myocardial infarction complicating pregnancy—a role for prostacyclin synthesis stimulating plasma factor and lipoprotein (a)?. **83:**237
Ulm, M.R., see Sinzinger, H. **84:**475
Ulutin, T., see Süer, S. **83:**77
Urano, T., see Malyszko, J. **81:**397
———, see Mochizuki, M. **81:**583
———, see Rydzewski, A. **84:**445
Uzan, A., see André, P. **83:**127

Vaage, J., see Valen, G. **83:**321
———, see Winnerkvist, A. **82:**533
Vaglini, M., see Bottasso, B. **81:**345
Vahland, M., see Storck, J. **84:**463
Vaillot, M., see Millet, J. **81:**497
Valanzano, R., see Chiarantini, E. **82:**137
Valen, G., O. Sigurdardottir, J. Vaage. Systemic release of thrombomodulin, but not from the cardioplegic, reperfused heart during open heart surgery. **83:**321
Valen, G., see Winnerkvist, A. **82:**533
van Gelder, J.M., C.H. Nair, D.P. Dhall. Erythrocyte aggregation and erythrocyte deformability modify the permeability of erythrocyte enriched fibrin network. **82:**33

Vannini, M.L., see Marongiu, F. **84:**379
Vayá, A., see Martínez, M. **83:**375
Veitl, M., A. Hamwi, A. Kurtaran, I. Virgolini, Th. Vukovich. Comparison of four rapid D-dimer tests for diagnosis of pulmonary embolism. **82:**399
Velander, W., see Lee, T.K. **82:**225
Veltmann, H., see Vielhaber, H. **81:**651
Vertolli, U., see Cella, G. **81:**671
Vianello, A., see Cella, G. **81:**671
Vickers, M., see Bessos, H. **84:**367
Vielhaber, H., B. Kohlhase, H.G. Koch, H.G. Kehl, M. Fliedner, D. Kececioglu, B. Kehrel, H. Veltmann, J. Vogt, U. Nowak-Göttl. Flush heparin during cardiac catheterisation prevents long-term coagulation activation in children without APC-resistance—preliminary results. **81:**651
Vielhaber, H., see Nowak-Göttl, U. **81:**665
Vieri, M., see Basili, S. **84:**279
Viinikka, L., see Turunen, P. **81:**635
Violi, F., see Basili, S. **84:**279
Virgolini, I., see Veitl, M. **82:**399
Vogel, G., C.-E. Dempfle, M. Spannagl, W. Leskopf. The value of quantitative fibrin monomer determination in the early diagnosis of postoperative deep vein thrombosis. **81:**241
Vogt, J., see Vielhaber, H. **81:**651
von Schenck, H., see Zöller, B. **83:**475
Vukovich, Th., see Veitl, M. **82:**399
Vun, C.M., S. Evans, B.H. Chong. Cross-reactivity study of low molecular weight heparins and heparinoid in heparin-induced thrombocytopenia. **81:**525

Wagner, K., see Lacroix, K.A. **81:**133
Wahl, P., see Marckmann, P. **82:**439
Walenga, J.M., see Kaiser, B. **82:**257
Wan, H., see Xia, L. **81:**477
Wanaka, K., S. Okamoto, N. Horie, A. Hijikata-Okunomiya, U. Okamoto, T. Naito, N. Ohno, M. Bohgaki, Y. Tsuda, Y. Okada. Use of an active center-directed plasmin inhibitor elucidates the multiplicity of plasmin actions. **82:**79
Wanaka, K., see Katsuura, Y. **82:**361
Wang, C.-T., see Faung, S.-T. **81:**91
Wang, S.-J., see Shi, G.-Y. **81:**75
Wareham, N.J., see Rota, S. **83:**329
Warnes, G., see Amirkhosravi, A. **84:**323
Watala, C., see Golański, J. **83:**199
Watson, C.A., see Wong, P.C. **83:**117
Weissbach, G., see Knöfler, R. **84:**157
Wenger, N.K., see Hooper, W.C. **81:**577
Werle, E., see Grau, A.J. **82:**245
Westerlund, G., see Holst, J. **81:**461
White, J.G., G.H.R. Rao. Aggregated-disaggregated, refractory platelets retain sensitivity to ristocetin. **84:**253
Wiesel, M.-L., see Kretz, J.-G. **84:**391
Williams, S.B., see Gralnick, H.R. **81:**113
Wiman, B., see Winnerkvist, A. **82:**533
Wing, L.-Y.C., see Shi, G.-Y. **81:**75
Winnerkvist, A., B. Wiman, G. Valen, J. Vaage. Release of tissue plasminogen activator during reperfusion after different times of ischaemia in isolated, perfused rat hearts. **82:**533
Winther, K., see Mieszczak, C. **84:**285
Wisløff, F., see Jacobsen, E.M. **82:**445, 83:339,
Wolski, Z., see Ziętek, Z. **83:**399
Wong, K., X.-B. Li. C_6-ceramide maintains elevated cytosolic calcium levels in activated platelets. **81:**219
Wong, P.C., E.J. Crain, Jr., O. Nguan, C.A. Watson, A. Racanelli. Antithrombotic actions of selective inhibitors of blood coagulation factor Xa in rat models of thrombosis. **83:**117
Wu, H.-L., see Shi, G.-Y. **81:**75

Xia, L., J. Gu, X. Zhang, Y. Liu, H. Wan, P. Li, C. Ruan. Preparation of an antifibrin thrombus-specific murine/human chimeric monoclonal antibody Fab fragment in escherichia coli. **81:**477
Xu, N., L. Zhou, A.-K. Öhlin, Å. Nilsson. Catabolism of prothrombin-chylomicron complexes *in vivo* in the rat. **81:**203

Yamamoto, C., see Fujii, N. **82:**379
———, see Kaji, T. **82:**389
Yamamoto, M., see Sawamoto, Y. **83:**279
Yamazaki, T., A. Katsumi, S. Tsuzuki, I. Sugiura, T. Kojima, J. Takamatsu, H. Saito. Analysis for antithrombin gene polymorphisms in Japanese subjects and cosegregation studies in families with hereditary antithrombin deficiency. **82:**275
Yang, L., see Satoh, K. **81:**515
Yang, L.H., D. Callas, J.M. Herbert, J. Fareed. Modulation of platelet function and vascular smooth muscle contractile actions by a novel, selective, highly potent 5-HT_2 antagonist (SR46349). **81:**555
Yang, L.H., D.A. Hoppensteadt, O. Iqbal, J. Fareed. Defibrotide mediated inhibition of serotonin, endothelin-I, thromboxane, and serum induced contraction of canine femoral and pulmonary arterial rings. **84:**167
Yatomi, Y., see Qi, R. **81:**43
———, see Satoh, K. **81:**515
Yen, M.-H., see Chou, T.-C. **84:**83
Ylikorkala, O., see Turunen, P. **81:**635
Yoshioka, A., see Sawamoto, Y. **83:**279
———, see Takamiya, O. **81:**657
Young, N.S., see Maciejewski, J.P. **83:**433
Yu, M., see Maciejewski, J.P. **83:**433

Zamboni, V., see Dettori, A.G. **83:**103
———, see Kretz, J.-G. **84:**391
Zarnitsina, V.I., A.V. Pokhilko, F.I. Ataullakhanov. A mathematical model for the spatio-temporal dynamics of intrinsic pathway of blood coagulation. I. The model description. **84:**225
———. A mathematical model for the spatio-temporal dynamics of intrinsic pathway of blood coagulation. II. Results. **84:**333
Zawilska, K., see Lewandowski, K. **81:**615, 693
Zehetgruber, M., R. Beckmann, H. Gabriel, G. Christ, B.R. Binder, K. Huber. The ACE-inhibitor lisinopril affects plasma insulin levels but not fibrinolytic parameters. **83:**143
Zhang, X., see Xia, L. **81:**477
Zheng, R.Q.H., see Stephens, A.C. **81:**545
Zhou, L., see Xu, N. **81:**203
Zielinski, C., see Pirich, C. **81:**213
Ziętek, Z., I. Iwan-Ziętek, R. Paczulski, M. Kotschy, Z. Wolski. Von Willebrand factor antigen in blood plasma of patients with urinary bladder carcinoma. **83:**399
Zimmermann, E.R., see Storck, J. **81:**121, **84:**463
Zivelin, A., L.V.M. Rao, S.I. Rapaport. Plasma PIVKA proteins in rabbits given warfarin. **82:**429
Zöller, B., L. Norlund, H. Leksell, J.-E. Nilsson, H. von Schenck, U. Rosén, J.-O. Jepsson, B. Dahlbäck. High prevalence of the FVR506Q mutation causing APC resistance in a region of southern Sweden with a high incidence of venous thrombosis (Letter to the Editors-in-Chief). **83:**475
Zozulińska, M., see Lewandowski, K. **81:**615
Zuppiroli, A., see Martini, F. **83:**299
Zwaal, R.F.A., see Smeets, E.F. **81:**419

Pergamon

Thrombosis Research 88 (1997) 521–525

THROMBOSIS RESEARCH

Keyword Index Volumes 81–84 (1996)

ABO blood-typing **84:**179
activated factor VII **81:**345, 687; **82:**235
activated factor XII **83:**469
activated human protein C **82:**147
activated leukocytes **82:**97
activated protein C resistance **81:**595; **82:**193; **83:**243, 363
activators to fibrinolysis **81:**133
active oxygen species **82:**303
acute myocardial infarction **82:**313
acute renal failure **83:**351
adenosine diphosphate **82:**57
adhesion **82:**485
adult respiratory distress syndrome **82:**97
Aedes communis **81:**623
age **84:**179
aggregate size **81:**515
aggregates **82:**169
aggregation **81:**101, 641; **82:**291; **84:**213, 285
albumin **81:**383
allergic reaction **83:**279
alpha 2 adrenergic receptor **81:**85
alpha-2 beta-1 **82:**485
ammonia **81:**195
anaesthetic procedure **81:**297
ancrod **81:**187
angiodysplasia **84:**385
angiography **83:**265
angioplasty **82:**459
animal model **81:**427
annexin V **82:**509
antagonist **82:**495
antibodies **84:**217
anticardiolipin **84:**217
anticoagulants **83:**199, 253
anticoagulation **84:**285
antigen **81:**545
antiphospholipid **84:**361
antiphospholipid antibodies **81:**693; **82:**43, 445; **83:**183
α2-antiplasmin **82:**129
antiplatelet agents **84:**279
antithrombin **82:**109, 275; **84:**137, 419
antithrombin potency **83:**97
antithrombotic activity **83:**217
aortic atheromatosis **84:**145
APC **81:**151
APC resistance **81:**151, 687; **82:**217, 235, 281; **83:**87, 475
APC-R **81:**577
APCR **81:**651, 665; **84:**203
apheresis **84:**367
apical membrane domain **81:**1
apolipoprotein A **81:**213
apolipoprotein AI **81:**597
APTT **83:**87, 137
APTT-based method **81:**665
arachidonic acid **82:**323
arachidonic acid release **83:**449
Arg^{506} **83:**87
Arg 506 Gln **81:**665
argatroban **82:**187, **83:**97, 463
arterial smooth muscle ring **84:**167
arterial thrombosis **81:**187; **82:**69, 453, 469; **84:**189
aspirin **81:**339, 615; **82:**453, 469; **83:**329; **84:**207
aspirin/dipyridamole **82:**479
assay **81:**419
atherosclerosis **81:**203; **82:**1, 335; **84:**129, 475
ATP release **84:**157
aurin tricarboxylic acid **81:**177
autoactivation **82:**119
autoantibodies **82:**207; **84:**97

baculovirus **81:**679
Behçet's disease **84:**297
biological half-life **81:**213
biosynthesis **83:**1
bladder carcinoma **83:**399
bleeding time **81:**187
blood coagulation **81:**533; **84:**225, 333
blood coagulation factors **81:**203, 253, 569
blood specimen handling **81:**253
blood transfusion **82:**409
bone alkaline phosphatase **84:**223
Buerger's disease **84:**445
bypass graft **82:**369

calcium **81:**163, 219; ;382:485
calcium transients **81:**1
calcium-dependent antibody **81:**65
calmodulin **81:**163
calpain **82:**509
cancer **84:**323
canine **83:**421
capillaries **84:**385
cardiac catheterisation **81:**651
cardiac surgery **83:**321
cardioplegia **83:**321
cardiopulmonary bypass surgery **84:**45
cardiovascular disease **81:**485; **84:**1
casein **81:**427
C4b-binding protein **81:**307
cell binding **84:**267
cell lysis **81:**91
cell-surface procoagulant **84:**453
ceramide **81:**219
γ-chain **81:**145
children **81:**471, 651
chimeric antibody **81:**477
cholestasis **81:**367
cholesterol **81:**419
cholesterol oxidation products **83:**449
chronic obstructive pulmonary disease **84:**295
chronic renal failure **83:**351
chylomicron **81:**583
ciprofibrate **84:**311
clot lysis **82:**177
clotting **81:**623
coagulation **81:**277; **82:**137, 409, 429; **84:**73, 285, 323
collagen **82:**485; **84:**345, 399
collagen binding **84:**55
compression sclerotherapy **82:**87
contact system **82:**265
contrast media **83:**265
COPD **84:**295
coronary circulation **82:**533
coronary heart disease **82:**245; **83:**77, 341
coumarin therapy **82:**217
C-reactive protein **81:**485; **82:**245
Crohn's disease **82:**137
crossed-immunoelectrophoresis **84:**137
crosslinking **84:**33, 129
cross-reactivity **81:**525
CTA **82:**159
cyclic AMP **82:**389
cyclic GMP **82:**543
cyclic guanosine monophosphate **82:**57
cyclooxygenase activity **84:**83
cyclosporin **83:**175
cyclosporin A **81:**367

0049-3848/97 $17.00 + .00 © 1998 Elsevier Science Ltd. Printed in the USA. All rights reserved.
PII S0049-3848(98)00067-X

cysteine proteinase inhibitors **82:**265
cytochalasin B **81:**515

Dami cell **82:**485
DD-antibodies **82:**169
D-dimer **82:**177, 459, 523
deep vein thrombosis **81:**241; **83:**153; **84:**297, 391, 431
defibrotide **84:**167
defibrotide bioavailability **81:**55
defibrotide pharmacokinetics **81:**55
deficiency **82:**275
delivery **82:**109
depolymerized holothurian glycosaminoglycan **83:**253
dermatan sulfate **82:**109
Desmin **83:**103
diabetic nephropathy **81:**485
diabetic retinopathy **81:**327
diagnostic testing **83:**137
diagnostic utility **82:**399
diet **82:**439
diluted activated partial thromboplastin time **82:**445
disseminated intravascular coagulation **82:**361
disulfated disaccharides **84:**21
docosahexaenoic acid **81:**283
DX-9065a **83:**117
dysfunctional fibrinogen variant **81:**145

EACA **82:**479
ecarin clotting time **83:**463
ECV304 cells **84:**453
EDTA **83:**199
efegatran sulfate **83:**97, 463
EGb 761 **82:**453
elastase **82:**177
elderly **83:**153
ELISA **83:**279
ellagic acid **82:**479
endothelial cells **81:**75, 121; **84:**267, 463
endothelial injury **82:**51; **83:**321
endothelin-I **84:**167
endothelium **82:**533
endotoxin **83:**405
enzyme **81:**623
enzyme linked immunosorbent assay **81:**253
epinephrine **81:**85, 515; **84:**351
epitope mapping **81:**65
erythrocyte aggregation **82:**33
erythrocyte deformability **81:**283; **82:**33, 159
erythrocyte membrane lipids **83:**375
estrogen **84:**1
evolution **83:**1
experimental animal model **81:**297
experimental thrombosis **81:**461; **84:**411
extracorporeal circulation **84:**45

F1+2 **83:**299
factor II **84:**411
factor IX **81:**65
factor V **81:**595; **82:**147, 193; **83:**87, 243, 475; **84:**361
factor V Leiden **82:**217, 281
factor V mutation **83:**363
factor VII **81:**1, 491; **82:**119; **84:**237
factor VII activation **81:**491
factor VII activity **81:**657
factor VIIa **81:**491, **84:**73, 237
factor VIII **82:**147; **84:**55
factor X **84:**73
factor Xa **81:**383, 533; **83:**117, 161
factor XII **83:**403
familial defect **81:**85
familial hypercholesterolemia **83:**375
family studies **82:**275
fibrin **81:**477; **82:** 33, 177; **83:**1
fibrin degradation products **81:**253
fibrin gel **84:**129
fibrin monomer **81:**241; **82:**523
fibrinogen **81:**187, 427, 485, 503; **82:**169, 245, 495, 523; **83:**1; **84:**199
fibrinogen degradation products **81:**253
fibrinogen glue **82:**349
fibrinogen mRNA **81:**263
fibrinogen synthesis **81:**263
fibrinolysis **81:**133, 277, 397; **82:**33, 137, 177, 303, 369, 409; **83:**1, 421; **84:**121, 179
fibrinopeptide A **81:**569; **84:**45
fish oil **81:**283
FK633 **81:**439
Flavobacterium ranacida **81:**91
flow cytometry **81:**533; **82:**257
flush heparin **81:**651
free radicals **83:**229; **84:**207
fusion proteins **84:**419
FVII-TF binding **81:**657

gamma glutamyl transferase **81:**271
gender **82:**439
gene expression **81:**1
gene polymorphism **82:**275
Gla-domain **81:**657
glucose tolerance test **83:**143
glycocalicin **81:**339; **84:**367
glycogen storage disease **82:**159
glycoprotein **82:**495
glycoprotein 330 **83:**161
glycoprotein Ib/IX **84:**253
glycoprotein IIb/IIIa **81:**515
glycosaminoglycan **83:**253; **84:**111
glycosaminoglycans **82:**379, 389; **84:**267
glycosylphosphatidylinositol **83:**433
GP Ib **84:**351
GPIb-α **81:**113
GPIIb/IIIa **81:**101; **82:**495
GPIIb/IIIa antagonist **81:**439
GPIb/IX **83:**127
GPIIIa **81:**353
guanylyl cyclase **82:**543
guinea pig blood **83:**127

haemophilia B **83:**279
haemorrhage **82:**409; **84:**111
haemostasis **81:**569; **82:**409; **83:**237; **84:**237, 385
HDL-cholesterol **81:**213
healthy volunteers **83:**103
heart **82:**533
heat treatment **82:**349
hemodialysis **81:**671
hemolysis **83:**433
hemorheology **83:**375
hemorrhagic activity **83:**217
hemorrhagic diathesis **82:**129
hemorrhagic shock **82:**97
hemostasis **82:**69; **83:**299, 351
hemostasis activation **82:**87
heparan sulfate **82:**379, 389
heparin **81:**383, 503, 525, 615, 671; **82:**187, 479; **83:**117, 265; **84:**55, 207, 295
heparin associated thrombocytopenia **81:**641
heparin cofactor II **82:**109; **84:**21
heparin derivatives **83:**217
heparin neutralisation **84:**237
heparin-induced platelet activation assay **81:**641
heparin-induced thrombocytopenia **81:**525
heparinoid **81:**525
hepatocellular carcinoma **84:**137
hepatocyte **81:**307
HepG-2 **81:**307, 315
2-heteroaryl 2′-substituted-phenyl ketone derivatives **84:**83
high-density lipoprotein **81:**597
hirudin **81:**157; **82:**187; **83:**97, 463; **84:**289, 419
hirulog-1 **82:**187
histidine-rich glycoprotein **84:**179
histones **82:**43
HIV-1 infection **81:**213
HMG-CoA reductase inhibitor **81:**397
homocysteine **83:**195, 243
homologous serum **81:**497
hormonal replacement therapy **84:**1
1*H*-[1,2,4]oxadiazolo[4,3-*a*]quinoxalin-1-one (ODQ) **82:**543
5-HT **81:**555
5-HT_2 antagonist **84:**445
5-HT_2 receptor antagonist **81:**555
human platelets **82:**57
humans **84:**157
hyaluronic acid **81:**383
hypercapnia **84:**295
hypercholesterolemia **81:**277
hypercoagulability **81:**241, 345
hypercoagulable **82:**479; **84:**411
hypercoagulable state **82:**235
hyperlipidaemia **82:**159
hypertension **83:**175
hypertriglyceridaemia **84:**311
hypertriglyceridemia **81:**203
hypoxia **84:**295

[^{125}I]-Defibrotide **81:**55
IgG subclass **83:**279
IL-1 **81:**307, 315
IL-6 **81:**307, 315
i.m. **83:**103
immunoassays **81:** 559, 607
immunoglobulin gene **81:**477
immunogold cytochemistry **84:**253
impedance aggregometry **81:**471
in situ hybridization **81:**545
infancy **81:**665
inflammatory bowel disease **82:**137
inhibition of thrombin **84:**21
inhibitor **83:**279
inhibitors to fibrinolysis **81:**133
inositol phosphate **81:**219
INR **84:**379
insulin **82:**57; **83:**143
insulin resistance **81:**271
insulin-dependent diabetes **82:**207
insulin-dependent diabetes mellitus **81:**485
integrin $\alpha_{IIb}\beta_3$ **83:**199
interleukin-6 **81:**485
intracellular Ca^{2+} concentration **81:**43
intravenous administration **84:**391
intrinsic pathway **84:**225, 333
ischaemia **82:**533
ischemia-reperfusion **83:**321

Japanese **81:**595

kallikrein-like activity **83:**469
kaolin clotting time **82:**445
ketanserin **81:**43, 555
kinetics **83:**189
kinin **82:**79
kininogens **82:**265; **84:**97

lactoferrin **81:**597
L-arginine **81:**195
laser **82:**453
laser model **82:**469
LDL receptor-related protein **83:**161
LDL-apheresis **82:**291
leukocytes **82:**245; **83:**341
light scatter **81:**43
lipids **81:**397
lipoprotein (a) **83:**237
lipoproteins **81:**203
lisinopril **83:**143
LMWH **81:**461, 491; **82:**469
lovastatin **83:**375
low molecular mass dermatan sulfate **84:**21
low molecular weight dermatan sulphate **83:**103; **84:**391
low molecular weight heparin **81:**525, 615
Lp(a) **83:**77
lupus anticoagulant **82:**43, 445; **83:**137, 403; **84:**217
lupus coagulation inhibitor **83:**339
Lys-plasminogen **83:**421

M-1 **81:**43
magnesium **83:**341
malignant pleural mesothelioma **84:**121
mathematical model **84:**225, 333
MCI-9042 **81:**43
mechanical heart valves **81:**403
melanoma **81:**345
membrane fluidity **83:**449
menopause **84:**1
13-methyl myristate **81:**91
microcarrier **84:**453
microplate reader **84:**213
migration **84:**129
milk peptides **81:**427
mini-plasminogen **83:**421
mitral valve prolapse **83:**299
monoclonal antibody **84:**345
monocyte chemotactic protein-1 **83:**307
monocytes **81:**545
mosquito **81:**623
mRNA **81:**545
MTHFR gene **83:**243
multimerization **84:**55
multiple organ failure **82:**361
mutation **81:**595; **82:**193; **83:**475
myeloperoxidase **82:**97
myocardial infarction **81:**615; **82:**1; **83:**237, 329

Na^+/H^+ exchanger **81:**515
NAIT **81:**353
negatively charged leukocyte filter **83:**469
neuropathy **81:**213
neurotransmitters **84:**189
nitric oxide **81:**195; **82:**543
non-responders **81:**133
normalized APC-sensitivity ratio **82:**235
normocoagulable **84:**411
nutrition **82:**439

obesity **81:**271
oligonucleotide ligation assay **83:**87
oral administration **81:**55
oral anticoagulants **81:**403; **84:**379
osteocalcin **84:**223
oversulfated sequences **84:**21
oxysterols **83:**449

PAI activity **81:**75
PAI-1 gene **84:**431
PAR-2 **84:**463
paroxysmal nocturnal hemoglobinuria (PNH) **83:**433
passive smoking **81:**451
PCA **81:**151
PCR **81:**353; **82:**193
[^{32}P]-Defibrotide **81:**55
peptide **84:**73
percutaneous transluminal coronary angioplasty **81:**687
perfusion chromatography **81:**503
peripheral arterial disease **81:**641; **82:**369, 523
peripheral ischaemia **81:**693
permeability **82:**33
pharmacokinetics **81:**461
phorbol 13-myristate acetate **82:**323
phosphatidylethanolamine **81:**419; **84:**97
phosphatidylserine **81:**419, 533
phospholipase A_2 **82:**323
phospholipid classes **81:**419
phosphoprotein phosphatase 1 **84:**399
pig haemostasis **81:**297
PIVKA **82:**429
PI^A **81:**353
placenta fibrinoid **81:**263
plasma kallikrein **82:**361
plasma PAI-1 **84:**431
plasma plasminogen activator inhibitor-1 (PAI-1) **81:**271
plasmin **81:**75; **82:**79; **84:**243
plasmin inhibitor, $\alpha 2$ **82:**129
plasmin inhibitor deficiency **82:**129
plasmin-α_2-antiplasmin **82:**409
plasminogen **84:**243
plasminogen activator inhibitor-1 **82:**369; **83:**143
platelet **81:**85; **82:**495; **83:**433; **84:**345, 399
platelet activation **82:**257; **83:**199
platelet adhesion **81:**177, 641; **82:**523
platelet age **84:**67
platelet aggregation **81:**177, 397, 407, 427, 439, 471, 511, 515, 583, 635; **82:**57, 523, 543; **83:**449; **84:97,** 279, 399
platelet aggregation test **81:**525
platelet factor 4 **81:**615
platelet function **81:**91; **84:** 83, 445
platelet glycoprotein Ib **81:**679
platelet 5-hydroxytryptamine **84:**67
platelet membrane **83:**199
platelet membrane microvesiculation **82:**509
platelet phospholipid-dependent thrombin generation **83:**329
platelet poor plasma **82:**323
platelet survival **82:**291
platelet thromboxane **81:**451
platelet von Willebrand factor **83:**287
platelet-derived growth factor-BB **83:**307
platelets **81:**43, 163, 219, 327, 367; **82:**417, 469; **83:**1, 265, 299, 341, 351, 405; **84:**213, 285, 367, 475
pleural fluid **84:**121
Pluronic® F-68 **81:**511
poloxamer-188 **81:**511
polymerization defect **81:**145
polymorphism **84:**431
post partum period **82:**109
pregnancy **82:**207; **83:**237; **84:**199, 203
premature labor **83:**243
prethrombosis markers **81:**241
prethrombotic state **83:**153; **84:**289

primary antiphospholipid syndrome **83:**183
procoagulant activity **82:**335, 509
procollagen-1-carboxyterminal peptide **84:**223
progestin **84:**1
progestogen **81:**407
prostacyclin **81:**327, 367; **82:**323
prostacyclin stimulating plasma factor **84:**475
prostacyclin synthesis stimulating plasma factor **83:**237
prostaglandin E_1 **82:**291
prostaglandin endoperoxide synthase **82:**323
prostaglandin I_2 **81:**213; **82:**291; **84:**475
Protac **82:**225
protein binding **83:**253
protein C **81:**151, 577; **82:**225; **83:**389, 475
protein kinase C **81:**163; **82:**323, 379, 417
protein S **81:**151, 315; **82:**147; **84:**223
proteinase **82:**303
proteinase activated receptor **84:**463
proteinase inhibitors **83:**339
proteoglycan **83:**161
prothrombin F 1+2 **81:**403
prothrombin fragment 1.2 **81:**671; **84:**45
prothrombin fragments 1+2 **82:**459; **84:**199
prothrombin time **84:**379
prothrombinase complex **81:**419
P-selectin **82:**97; **83:**299
PTP **81:**353
pulmonary disease **84:**279
pulmonary embolism **82:**399; **83:**243
pulmonary vascular injury **82:**97
pyrimido-pyrimidine derivatives **81:**327

quality **84:**367
quality control **81:**253
quantification **84:**157

rabbits **82:**429
race prevalence **81:**577
rapid D-dimer tests **82:**399
rat **81:**187, 283, 497; **82:**69, 147, 533; **83:**405; **84:**111
rat fibrinogen peptides **81:**231
rat pulmonary artery **81:**231
receptor **81:**597
receptor density **84:**253
recombinant **84:**373
recombinant von Willebrand factor **84:**55
refractory platelets **84:**253
release **83:**189
remnant lipoprotein **81:**583
reperfusion **82:**533
retinal vein occlusion **83:**183
risk factors **84:**1
ristocetin agglutination **84:**253
ristocetin cofactor activity **84:**55
ritanserin **81:**555
Rose Bengal **83:**229
r-proUK **83:**421
r-UK **83:**421

salmon **83:**389
sarpogrelate **84:**445
SC-49992 **81:**101
serine proteinase **84:**373
serotonin **81:**43, 397; **83:**175, 189, 351; **84:**167, 445
serotonin antagonist **81:**43
serum **84:**167
sex **82:**439
shape change **81:**43, 163
shear **84:**351
SHRSP **82:**417
SLIGRL **84:**463
smooth muscle cells **82:**323; **84:**129
snake venoms **83:**389
sodium nitroprusside **82:**543
soluble fibrin **81:**253, 569, 607
Sonoclot™ analysis **84:**323
spatial dynamics **84:**225, 333
species specificity **81:**1; **82:**147
sphingomyelin **81:**419
sphingosine **82:**119
SR46349 **81:**555
SR46615 **81:**555
stagnation point flow adhesio-aggregometry **81:**641; **82:**523
stasis **81:**497
steatosis **81:**271
stenosis **81:**101
storage markers **84:**367
streptozotocin **84:**311
stroke **82:**245
structure **82:**349
subendothelium **81:**177
sulphation **81:**383
surface plasmon resonance **81:**503
synthetic inhibitor **82:**79
synthetic protease inhibitor **82:**361
systemic embolism **84:**145
systemic lupus erythematosus **84:**217, 361
systemic sclerosis **81:**693

tacrolimus **83:**175
teleosts **83:**389
Textarin® **83:**363
TFPI **81:**461; **84:**237
therapy **84:**391
α-thrombin **84:**33
thrombin **81:**157, 177, 533, 623, 635; **82:**109, 225; **84:**45, 97, 225, 289, 333, 373, 419
thrombin determination **81:**157
thrombin inhibitors **82:**257; **83:**97, 463
thrombin receptor **81:**121; **84:**463
thrombin-antithrombin complex **81:**671; **82:**523
thrombin-antithrombin III complex **82:**87, 409, 459
thrombin-like **81:**623
thrombin-like activity **83:**469
β-thromboglobulin **81:**615, 671
thrombolytic therapy **82:**313
thrombomodulin **82:**51, 225, 313, 439, **83:**321; **84:**373
thrombophilia **83:**195
thromboplastin **83:**339; **84:**379
thromboresistance **84:**475
thrombosis **81:**113, 315, 427, 439, 577, 635, 687; **82:**1, 235, 335; **83:**1, 117, 127, 195, 229, 433, 475; **84:**129, 179, 207, 361
thrombotic events **83:**175
thromboxane **81:**327, 367, 407; **84:**167
thromboxane A_2 **81:**515; **84:**83
thrombus **84:**351
tick anticoagulant peptide **83:**117
tissue factor **81:**1, 545; **82:**335; **83:**307; **84:**73, 267, 323, 453
tissue factor pathway inhibitor **83:**161; **84:**267
tissue factor pathway inhibitor activity **81:**671
tissue plaminogen activator **82:**533; **83:**143
tissue-type plasminogen activator **82:**369
TNF **81:**307, 315
t-PA **82:**169
t-PA-PAI-1 complex **83:**77
transcatheter arterial embolization **84:**137
transesophageal echocardiography **84:**145
transgenic pig **82:**225
transient ischaemic attack **81:**339
transit time **82:**159
traveller **83:**153
treatment **84:**295
trophoblasts **81:**263
trout **83:**389
tumor growth **82:**79

UFH **81:**491
ulcerative colitis **82:**137
uptake **83:**189
uremia **83:**189
urokinase **84:**243
urokinase receptor **84:**243

Vaccinium myrtillus **84:**311
valproic acid **81:**471
vascular changes **82:**129
vascular endothelial cells **82:**379, 389
vascular risk factors **82:**245
vascular wall **84:**475
vasoactive effects **81:**231
vasoconstriction **84:**189
vasodilatation **81:**635; **84:**189
venous occlusion **81:**133
venous thrombosis **81:**187, 497; **82:**469; **84:**311
venous thrombus formation **84:**111

vibration syndrome **82:**51
VLA-2 **81:**113
VLDL **81:**583
von Willebrand disease **83:**287
von Willebrand factor **81:**121, 177; **84:**351, 463
von Willebrand factor antigen **83:**399
vWD **84:**385
vWF **83:**127
vWF receptor **81:**679

warfarin **81:**657; **82:**429; **84:**285, 411
whole blood **81:**471; **84:**157
WKS motif **84:**73
WKY **82:**417

Yersinia pestis **84:**33
YopM **84:**33
Yoshida rats **84:**311